Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

> Stock Exchange Code: 4997 June 2, 2021

To Shareholders with Voting Rights:

Yosuke Tomoi Representative Director, President NIHON NOHYAKU CO., LTD. 19-8, Kyobashi 1-Chome, Chuo-ku, Tokyo, Japan

NOTICE OF

THE 122ND ORDINARY GENERAL MEETING OF SHAREHOLDERS

Dear Shareholders:

We would like to express our appreciation for your continued support and patronage.

The 122nd Ordinary General Meeting of Shareholders of NIHON NOHYAKU CO., LTD. (hereinafter referred to as the "Company") will be held for the purposes as described below.

To prevent the spread of COVID-19, we hereby kindly but firmly ask shareholders to exercise your voting rights in writing or via the Internet wherever possible, rather than to attend the General Meeting, regardless of health condition.

Please review the attached Reference Documents for the General Meeting of Shareholders and, following the instruction hereinafter described, exercise your voting rights by 5:25 p.m. on Tuesday, June 22, 2021, Japan time.

- 1. Date and Time: Wednesday, June 23, 2021 at 10:00 a.m. Japan time
- 2. Place:

Banquet hall Ariake on the 2nd floor of Royal Park Hotel

located at 1-1, Nihonbashi-Kakigara-cho 2-Chome, Chuo-ku, Tokyo, Japan As part of the infection control measures against the novel coronavirus, we will arrange wider distance between seats, resulting in far fewer seats this year than normally available in ordinary years, as was the case the last year. As such, some of shareholders may not be accommodated in the venue, for which your kind understanding would be appreciated.

3. Meeting Agenda:

- Matters to be reported: 1. The Business Report, Consolidated Financial Statements for the Company's 122nd Fiscal Year (April 1, 2020 - March 31, 2021) and results of audits by the Accounting Auditor and the Audit & Supervisory Committee of the **Consolidated Financial Statements**
 - 2. Non-consolidated Financial Statements for the Company's 122nd Fiscal Year (April 1, 2020 - March 31, 2021)

Proposals to be resolved:

Proposal 1:	Appropriation of Surplus
Proposal 2:	Election of 10 Directors (Excluding Directors Serving as the Audit &
	Supervisory Committee Members)

4. Instruction for Exercising Voting Rights:

If you are attending the General Meeting of Shareholders

Please submit the enclosed Voting Rights Exercise Form at the reception desk.

Date and Time of the Meeting	Wednesday, June 23, 2021 at 10:00 a.m. Japan time
If you are not attending the General Me	eting of Shareholders, please exercise your voting

rights either via postal mail or the Internet.

Exercise of voting rights by postal mail

Please indicate your approval or disapproval of the proposals on the attached Voting Rights Exercise Form and return it by the deadline.

Deadline of Exercise	Tuesday, June 22, 2021 at 5:25 p.m. Japan time
----------------------	--

Exercise of voting rights via the Internet

Please access the Company's designated voting rights exercise website (https://www.web54.net) and use the "voting rights exercise code" and "password" indicated on the enclosed Voting Rights Exercise Form, and follow the instructions on the screen to enter your vote for or against the proposals by the deadline.

For details, please refer to page 3 of the Japanese version of this document.

Deadline of Exercise	Tuesday, June 22, 2021 at 5:25 p.m. Japan time
----------------------	--

If you exercise your voting rights using a smartphone, please use "Smart Voting." * Please refer to the enclosed flier for details.

If your voting rights are exercised in duplicate both in writing and via the Internet, etc., the vote via the Internet, etc. shall be deemed valid. When voting rights are exercised multiple times via the Internet, etc., or in duplicate using a PC or smartphone, the last vote shall be deemed valid.

<Requests to our shareholders>

- The aforementioned procedures may be changed depending on the latest development concerning the COVID-19 pandemic, or on the announcement by the government and other authorities. Shareholders are asked to check the latest information posted on the Company's website (https://www.nichino.co.jp/) (Japanese only).
- Exercise of voting rights by mail should involve infection risk in the processes including returning by post and aggregation at the Company. Therefore, we would like to ask you to exercise your voting rights via the Internet, etc. wherever possible, if you opt for voting in advance.
- Hand sanitizers shall be placed for shareholders at the entrance to the venue.
- Shareholders attending the meeting are kindly asked to bring and wear a face mask.
- We will be checking your body temperatures at the entrance to the venue. Shareholders found to have a fever of 37.5 degrees Celsius or higher, those not feeling well, and those having returned from overseas in the past 14 days may be asked not to enter the venue and go home. Shareholders having returned from overseas in the past 14 days would be requested to report to the reception.
- Staff at the venue for organizing the General Meeting will be checked for their body temperature and physical condition in advance and will be wearing a face mask.
- With a view to reducing the time of the meeting thereby minimizing the risk of infection, we decided not to present detailed explanation about the proposals for the General Meeting. As such, shareholders attending the General Meeting in person are asked to go through this notice in advance.

- If you are exercising your voting rights by proxy, you can delegate the exercise of your voting rights to another shareholder, who also owns voting rights. In such a case, please have your proxy submit a written power of attorney.
- © The following matters are provided on the Company's website (https://www.nichino.co.jp/) pursuant to laws and regulations and Article 15 of the Company's Articles of Incorporation, and are thus not included with this notice.
 - (1) "III. Structures and policies of the company" and "IV. Other significant matters regarding the current status of the corporate group" of the Business Report
 - (2) "Consolidated Statement of Changes in Equity" and "Notes to the Consolidated Financial Statements" of the Consolidated Financial Statements
 - (3) "Non-consolidated Statement of Changes in Equity" and "Notes to the Non-consolidated Financial Statements" of the Non-consolidated Financial Statements
- © Should the attached documents and Reference Documents for the General Meeting of Shareholders of this convocation notice require revisions, the revised versions will be posted on the Company's website (https://www.nichino.co.jp/) (Japanese only).
- A video recording of the proceedings of the General Meeting is planned to be posted on the Company's website (https://www.nichino.co.jp/ir/page_10094.html) (Japanese only) about one week after the day of the event.

Reference Documents for the General Meeting of Shareholders

Proposals and References

Proposal 1: Appropriation of Surplus

The Company's basic policy is to distribute stable and continuous dividend of profits to shareholders through enhancing the corporate value by expanding the business revenue and strengthening financial standing from the long-term perspective.

Taking into account the above policy and performance during the current fiscal year, the appropriation of surplus for the 122nd fiscal year is proposed as follows.

Matters concerning the year-end dividend:

- Matters concerning the allotment of dividend property to shareholders and total amount thereof:
 7.50 yen per share of the Company's common stock, in a total amount of 590,806,650 yen
 Furthermore, as an interim dividend of 7.50 yen per share was provided, the annual dividend will be
 15 yen per share in total.
- (2) The effective date of the dividend of surplus

Thursday, June 24, 2021

Proposal 2: Election of 10 Directors (Excluding Directors Serving as the Audit & Supervisory Committee Members)

The terms of office of all 10 Directors (excluding Directors serving as the Audit & Supervisory Committee Members; hereinafter the same) will expire at the conclusion of this Ordinary General Meeting of Shareholders. Accordingly, the Company proposes the election of 10 Directors.

The Audit & Supervisory Committee deliberated this proposal and expressed its opinion that there are no matters to be pointed out.

The candidates for Director are as follows:

No.	Name	Current positions and responsibilities	Attributes	Attendance rate at Board of Directors meetings
1	Yosuke Tomoi	Representative Director, President	Re- election	100% (18 out of 18 meetings)
2	Koji Shishido	Representative Director and Senior Managing Executive Officer, Division Manager of Production Division, and in charge of Environment Safety Dept.	Re- election	100% (18 out of 18 meetings)
3	Hirohisa Yano	Director and Managing Executive Officer, Division Manager of Administration Division, responsible for Osaka Plant and General Manager of Osaka Plant, in charge of Market Development Division, and responsible for special missions	Re- election	100% (18 out of 18 meetings)
4	Hiroshi Yamanoi	Director and Senior Executive Officer, and Division Manager of Industrial & Pharmaceuticals Sales Division	Re- election	100% (18 out of 18 meetings)
5	Hideo Yamamoto	Director and Senior Executive Officer, and Division Manager of Domestic Sales Division	Re- election	100% (18 out of 18 meetings)
6	Hiroyuki Iwata	Director and Senior Executive Officer, and Division Manager of Corporate Planning Division	Re- election	100% (18 out of 18 meetings)
7	Akio Kohri	Director	Re- election	94% (17 out of 18 meetings)
8	Yasunori Matsui	Director	Re- election Outside Indepen- dent	100% (18 out of 18 meetings)
9	Kazuyoshi Tachibana	Director	Re- election Outside Indepen- dent	100% (16 out of 16 meetings)
10	Kozo Machiya	Managing Executive Officer and Division Manager of Research Division	New election	_
New electio		Outside	idate dent stipu	pendent officer ilated by stock anges, etc.

No.	Name (Data of hirth)		Past experience, positions, responsibilities	Number of shares of the
	(Date of birth)		and significant concurrent positions	Company held
		April 1980 December 2006	Joined the Company Executive Officer and General Manager of Corporate Planning Dept., Corporate Office Division	
		December 2007	Director and Executive Officer, General Manager of Corporate Office Division, General Manager of Corporate Planning Dept.,	
	Yosuke Tomoi (January 12, 1956)	December 2008	Corporate Office Division, and General Manager of Legal & Auditorial Dept., Corporate Office Division of the Company Director and Executive Officer, General Manager of Corporate Office Division, responsible for Secretarial Dept., and General	
	Reelection Attendance rate at	December 2009	Manager of Secretarial Dept. Director and Executive Officer, and Deputy Division Manager of Sales Division	34,972
	Board of Directors meetings 100%	August 2010	Director and Executive Officer, Deputy Division Manager of Sales Division, and General Manager of Sales Dept. 2, Sales Division	57,772
1	(18 out of 18 meetings)	December 2011	Director and Managing Executive Officer, General Manager of Corporate Office Division, responsible for Secretarial Dept., and General Manager of Secretarial Dept.	
		December 2014	Director and Senior Managing Executive Officer, General Manager of Corporate Office Division, responsible for Secretarial Dept., in charge of Administration Division, and General Manager of Secretarial Dept.	
		December 2015	Representative Director, President (current position)	
	[Special notes regarding	ng the candidate for	: Yosuke Tomoi and the Company.	
		April 1983	Joined Asahi Denka Co., Ltd. (current ADEKA Corporation)	
		June 2004	General Manager of Food Production Dept., Kashima Plant,	
	Koji Shishido		Asahi Denka Co., Ltd.	
	(December 20, 1959)	June 2010 June 2014	Plant Manager of Kashima Plant, ADEKA Corporation General Manager of Production Management Dept., ADEKA Corporation	
	Reelection	June 2016	Operation Operating Officer and General Manager of Environmental Protection Division, General Manager of Environmental Safety	17.000
	Attendance rate at Board of Directors meetings	April 2017	& Quality Assurance Dept., ADEKA Corporation Operating Officer and General Manager of Environmental Protection Division, ADEKA Corporation	17,906
2	100% (18 out of 18 meetings)	December 2018	Representative Director and Senior Managing Executive Officer, and Division Manager of Production Division	
2		June 2020	Representative Director and Senior Managing Executive Officer, Division Manager of Production Division, and in charge of Environment Safety Dept. (current position)	
	Operating Officer. In environmental protect 2018, and is currently Division. The Compa	as engaged in the a addition, he has ion segments and b and engaged in streng		production an the Company i the Production
	and achievements. [Special notes regardin			
			: Koji Shishido and the Company. served as an executive of ADEKA Corporation, the Company's	

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
3	Hirohisa Yano (July 16, 1958) Reelection Attendance rate at Board of Directors meetings 100% (18 out of 18 meetings)	April 1982 August 2007 December 2008 December 2011 August 2013 December 2015 August 2017 December 2018 June 2020	Joined the Company General Manager of Secretarial Dept. General Manager of Marketing Dept., Sales Division Executive Officer, Deputy Division Manager of Sales Division, General Manager of Marketing Dept., Sales Division Executive Officer, Deputy Division Manager of Sales Division Executive Officer, Deputy Division Manager of Sales Division Director and Senior Executive Officer, and Division Manager of Sales Division Director and Senior Executive Officer, and Division Manager of Domestic Sales Division Director and Senior Executive Officer, and Division Manager of Domestic Sales Division Director and Senior Executive Officer, and Division Manager of Market Development Division Director and Managing Executive Officer, Division Manager of Administration Division, responsible for Osaka Plant and General Manager of Osaka Plant, in charge of Market Development Division, and responsible for special missions (current position)	8,793
	[Reason for election as a candidate for Director] Mr. Hirohisa Yano has broad experience and knowledge gained by serving in the Company's sales segment, market development segment, and others. He assumed the office of Director of the Company in 2015 and is currently engaged in strengthening the administration segment as Division Manager of the Administration Division. The Company expects him to continuously contribute to revitalizing the Board of Directors by drawing on these experiences and achievements. [Special notes regarding the candidate for Director] There are no special interests between Mr. Hirohisa Yano and the Company.			

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
4	Hiroshi Yamanoi (January 22, 1958) Reelection Attendance rate at Board of Directors meetings 100% (18 out of 18 meetings)	April 1981 June 2007 October 2010 May 2011 June 2014 October 2016 December 2016 December 2018 August 2019 April 2020	Joined Adeka Argus Chemical Co., Ltd. (current ADEKA Corporation) General Manager of Additives Solution Dept., Polymer Additives R&D Laboratory, ADEKA Corporation General Manager of Additives Solution Dept., Polymer Additives R&D Laboratory, ADEKA Corporation General Manager of Overseas Business Promotion Office, Corporate Planning Dept., ADEKA Corporation General Manager of Affiliated Companies Support Office, Corporate Planning Dept., ADEKA Corporation Joined the Company Executive Adviser of Chemical Products Division Director and Senior Executive Officer, and Division Manager of Chemical Products Division Director and Senior Executive Officer, and responsible for Pharmaceuticals Dept. Director and Senior Executive Officer, and Division Manager of Industrial & Pharmaceuticals Sales Division Director and Senior Executive Officer, Division Manager of Industrial & Pharmaceuticals Sales Division Director and Senior Executive Officer, Division Manager of Industrial & Pharmaceuticals Dept., Industrial & Pharmaceuticals Sales Division	8,511
	Industrial & Pharmaceuticals Sales Division (current position)[Reason for election as a candidate for Director]Mr. Hiroshi Yamanoi has worked to promote and support overseas businesses in the corporate planning department of ADEKA Corporation, in addition to having engaged in research and development of additives solution at that company. He assumed the office of Director of the Company in 2016, and is currently engaged in strengthening the industrial and pharmaceuticals sales business including agrochemicals as Division Manager of the Industrial & Pharmaceuticals Sales Division. The Company expects him to continuously contribute to revitalizing the Board of Directors by drawing on these experiences and achievements.[Special notes regarding the candidate for Director] There are no special interests between Mr. Hiroshi Yamanoi and the Company. In the past, Mr. Hiroshi Yamanoi served for 10 years as an executive of ADEKA Corporation, the Company's parent company as described in past experience, positions, responsibilities and significant concurrent positions.			

NIa	Name		Past experience, positions, responsibilities	Number of
No.	(Date of birth)		and significant concurrent positions	shares of the
		1 1005		Company held
		April 1985 August 2006 December 2013	Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager of Accounting and System Dept., Administration Division	
	Hideo Yamamoto	December 2015	Executive Officer, Deputy Division Manager of Sales Division, and General Manager of Marketing Dept., Sales Division	
	(August 10, 1962)	December 2016	Executive Officer, Deputy Division Manager of Sales Division, and General Manager of Technical Service & Promotion Dept., Sales Division	
	Reelection Attendance rate at	December 2017	Executive Officer, Deputy Division Manager of Domestic Sales Division, General Manager of Technical Service & Promotion	6,929
	Board of Directors meetings	August 2018	Dept., Domestic Sales Division, and General Manager of Sales Dept. 1, Domestic Sales Division Executive Officer and Deputy Division Manager of Domestic	.,, _,
5	100% (18 out of 18 meetings)	December 2018	Sales Division Director and Senior Executive Officer, and Division Manager of	
	6,	April 2020	Domestic Sales Division Director and Senior Executive Officer, and Division Manager of Domestic Sales Division, General Manager of Smart Agriculture	
		April 2021	Promotion Dept., Domestic Sales Division Director and Senior Executive Officer, and Division Manager of Domestic Sales Division (current position)	
	segments of the Comp		ence and knowledge gained by serving in the domestic sales and he office of Director of the Company in 2018, and is engaged in st	
	domestic businesses revitalizing the Board	pany. He assumed t as Division Manag of Directors by dra	the office of Director of the Company in 2018, and is engaged in st ger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements.	trengthening th
	domestic businesses revitalizing the Board [Special notes regardi	bany. He assumed t as Division Manag of Directors by dra ng the candidate fo	the office of Director of the Company in 2018, and is engaged in st ger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director]	trengthening the
	domestic businesses revitalizing the Board [Special notes regardi There are no special in	pany. He assumed t as Division Manag of Directors by dra ng the candidate fo nterests between M	the office of Director of the Company in 2018, and is engaged in st ger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company.	trengthening th
	domestic businesses revitalizing the Board [Special notes regardi	bany. He assumed t as Division Manag of Directors by dra ng the candidate fo	the office of Director of the Company in 2018, and is engaged in st ger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director]	trengthening th
	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata	pany. He assumed t as Division Manag of Directors by dra ng the candidate fo nterests between M April 1986 December 2013	 the office of Director of the Company in 2018, and is engaged in steer of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas 	trengthening th
	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata (November 3, 1963) Reelection Attendance rate at Board of Directors	pany. He assumed t as Division Manag of Directors by dra ng the candidate fo nterests between M April 1986 December 2013 August 2016 December 2016	 the office of Director of the Company in 2018, and is engaged in siger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas Division, and General Manager of Sales Dept. Asia, Overseas Division 	trengthening the
6	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata (November 3, 1963) Reelection Attendance rate at Board of Directors meetings 100%	pany. He assumed t as Division Manag of Directors by dra ng the candidate for nterests between M April 1986 December 2013 August 2016 December 2016 December 2017 December 2018	 the office of Director of the Company in 2018, and is engaged in siger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas Division Executive Officer and Division Manager of Overseas Division Executive Officer and Division Manager of Overseas Division 	trengthening the to contribute to
6	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata (November 3, 1963) Reelection Attendance rate at Board of Directors meetings 100% (18 out of 18 meetings)	pany. He assumed t as Division Manag of Directors by dra ng the candidate for interests between M April 1986 December 2013 August 2016 December 2016 December 2017 December 2018 June 2020	 the office of Director of the Company in 2018, and is engaged in siger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas Division, and General Manager of Sales Dept. Asia, Overseas Division Executive Officer and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division 	trengthening th to contribute t
6	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata (November 3, 1963) Reelection Attendance rate at Board of Directors meetings 100% (18 out of 18 meetings) [Reason for election a Mr. Hiroyuki Iwata ha the Company. He as	pany. He assumed t as Division Manag of Directors by dra ng the candidate for nterests between M April 1986 December 2013 August 2016 December 2016 December 2017 December 2018 June 2020 as a candidate for D as broad experience sumed the office of	 the office of Director of the Company in 2018, and is engaged in siger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas Division Executive Officer and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Corporate Planning Division (current position) irector] e and knowledge gained by serving in the domestic and overseas safe Director of the Company in 2018, and is currently engaged 	9,002 slles segments of in creating an
6	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata (November 3, 1963) Reelection Attendance rate at Board of Directors meetings 100% (18 out of 18 meetings) [Reason for election a Mr. Hiroyuki Iwata ha the Company. He as advancing growth stra The Company expect achievements.	pany. He assumed t as Division Manag of Directors by dra ng the candidate for nterests between M April 1986 December 2013 August 2016 December 2016 December 2017 December 2017 December 2018 June 2020 is a candidate for D as broad experience sumed the office of ategies to realize th ts him to contribu	 the office of Director of the Company in 2018, and is engaged in siger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas Division, and General Manager of Sales Dept. Asia, Overseas Division Executive Officer and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director of the Company in 2018, and is currently engaged and knowledge gained by serving in the domestic and overseas set of Director of the Company in 2018, and is currently engaged and knowledge by serving the Board of Directors by drawing on these of the company in 2018. 	9,002 9,002 elles segments c in creating an unning Divisior
6	domestic businesses revitalizing the Board [Special notes regardi There are no special in Hiroyuki Iwata (November 3, 1963) Reelection Attendance rate at Board of Directors meetings 100% (18 out of 18 meetings) [Reason for election a Mr. Hiroyuki Iwata he the Company. He as advancing growth stra The Company expect achievements. [Special notes regardi	pany. He assumed t as Division Manag of Directors by dra ng the candidate for nterests between M April 1986 December 2013 August 2016 December 2016 December 2017 December 2017 December 2018 June 2020 as a candidate for D as broad experience sumed the office of ategies to realize th ts him to contribu	 the office of Director of the Company in 2018, and is engaged in siger of the Domestic Sales Division. The Company expects him wing on these experiences and achievements. r Director] r. Hideo Yamamoto and the Company. Joined the Company General Manager of Sales Dept. 1, Sales Division General Manager attached to Division Manager of Overseas Division Executive Officer, Deputy Division Manager of Overseas Division, and General Manager of Sales Dept. Asia, Overseas Division Executive Officer and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director and Senior Executive Officer, and Division Manager of Overseas Division Director of the Company in 2018, and is currently engaged and knowledge gained by serving in the domestic and overseas set of Director of the Company in 2018, and is currently engaged and knowledge by serving the Board of Directors by drawing on these of the company in 2018. 	9,002 9,002 elles segments c in creating an unning Division

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
7	Akio Kohri (December 21, 1948) Reelection Attendance rate at Board of Directors meetings 94% (17 out of 18 meetings)	April 1971 June 2008 June 2010 June 2012 December 2013 June 2018 June 2020 (Significant concu Advisor of ADER Outside Audit &	1 /	_
	engaged in business a insight. The Company adequate to serve as D [Liability limitation ag The Company has ent Companies Act. Subje his liability to the amo [Special notes regardi There are no special in For the past 10 year	s a candidate for D served as Chairmar dministration in the / has continuously birector. greement] ered into an agreen ect to the approval bount stipulated by la ng the candidate fo nterests between M s to the present, 1	irector] a and President of ADEKA Corporation, the Company's parent company and President of ADEKA Corporation, the Company's parent company for many years and has a wealth of expense selected him as a candidate for Director, because the Company because the Company because the Company because the Mr. Akio Kohri to limit his liability under Article 423, Pa of his election as Director, the Company intends to continue the against and regulations.	rience and broad elieves that he is aragraph 1 of the greement to limit Corporation, the

	Name		Past experience, positions, responsibilities	Number of	
No.	(Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	shares of the	
	(Date of offilin)		and significant concurrent positions	Company held	
	Yasunori Matsui (March 3, 1956) Reelection Outside Independent Attendance rate at Board of Directors	April 1984 April 1987 April 1990 April 1994 April 2006 March 2007 April 2008	Full-time lecturer of Department of Commerce, Faculty of Commerce at Takachiho University of Commerce (current Takachiho University) Associate professor of Department of Commerce, Faculty of Commerce, Takachiho University of Commerce Visiting researcher of the University of Exeter, U.K. Associate professor of Business Department, College of Economics, Rikkyo University Professor of Global Business Department, College of Business, Rikkyo University PhD (Accounting) (Rikkyo University) President of Graduate School of Business Administration (MBA), Rikkyo University		
	meetings 100% (18 out of 18 meetings)	April 2012 December 2014 December 2014 April 2021	Dean, College of Business, Rikkyo University CPA Examination Committee Member Director of the Company (current position) Professor of Ohara Graduate School of Accounting (current position)		
		(Significant concu Professor of Ohar			
 Reason for election as a candidate for Outside Director and overview of expected roles] Mr. Yasunori Matsui has broad knowledge and insight in business administration gained through many year as a university professor (in accounting and business administration), and by providing the Company wit advice on the Company's overall management from an objective perspective, he has contributed to effectiveness of the Company's Board of Directors. Although he has no experience in being involve management except as an outside officer, the Company has continuously selected him as a candidate for Obecause, in addition to the reasons mentioned above, the Company believes that he is capable of adequaduties relevant to the position based on his solid track record of fulfilling the responsibilities as Outside Company. The Company expects him to continue to fulfill the above roles. He will have served as Outside Director for 6 years and 6 months at the conclusion of this Ordinary Gene Shareholders. [Matters concerning independence] Mr. Yasunori Matsui satisfies the requirements for independent officer stipulated by the Tokyo Stock Independence Standards for Appointment of Independent Officers set forth by the Company. The Company. The Company 				th opinions and improving the ed in corporate Dutside Director, nately executing Director of the neral Meeting of	
	Director, the Company will notify the Exchange of his ongoing designation as an independent officer. [Liability limitation agreement] The Company has entered into an agreement with Mr. Yasunori Matsui to limit his liability under Article 423, I of the Companies Act. Subject to the approval of his election as Director, the Company intends to continue the aglimit his liability to the amount stipulated by laws and regulations. [Special notes regarding the candidate for Director]				
	There are no special interests between Mr. Yasunori Matsui and the Company.				

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held	
	Kazuyoshi Tachibana	April 1978	Joined Kyowa Hakko Kogyo Co., Ltd. (current Kyowa Kirin		
	(January 21, 1956)	I	Co., Ltd.)		
	· · · /	July 2002	President of Kyowa Pharmaceuticals Inc.		
	Reelection	April 2005	General Manager of Pharmaceutical Strategic Planning Division		
		-	and Pharmaceutical Manufacturing Strategy Department, Kyowa		
1	Outside		Hakko Kogyo Co., Ltd.		
		June 2005	Executive Officer of Kyowa Hakko Kogyo Co., Ltd.		
	Independent	October 2008	Executive Officer of Kyowa Hakko Kirin Co., Ltd. (current	2,000	
	_		Kyowa Kirin Co., Ltd)		
	Attendance rate at	April 2009	Managing Executive Officer of Kyowa Hakko Kirin Co., Ltd.		
	Board of Directors	June 2009	Director of the Board and Managing Executive Officer of Kyowa		
	meetings		Hakko Kirin Co., Ltd.		
	100%	March 2018	Retired from the office of Director of the Board and Managing		
	(16 out of 16		Executive Officer of Kyowa Hakko Kirin Co., Ltd.		
	meetings)	June 2020	Director of the Company (current position)		
	[Reason for election as a candidate for Outside Director and overview of expected roles]				
9	Mr. Kazuyoshi Tachibana has a wealth of experience and broad-based insight as operating officer of a listed company as				
9	well as manager of an overseas business entity, and by providing the Company with opinions and advice on the Company's				
			perspective, he has contributed to improving the effectiveness of		
	Board of Directors. The Company has selected him as a candidate for Outside Director, because the Company believes he is				
	capable of adequately executing duties relevant to the position. The Company expects him to continue to fulfill the above				
	roles.				
	He will have served as Outside Director for 1 year at the conclusion of this Ordinary General Meeting of Shareholders.				
		[Matters concerning independence]			
	Mr. Kazuyoshi Tachibana satisfies the requirements for independent officer stipulated by the Tokyo Stock Exchange and				
	Independence Standards for Appointment of Independent Officers set forth by the Company. The Company has designated				
	him as an independent officer and notified the Exchange to that effect. Subject to the approval of his election as Outside				
			change of his ongoing designation as an independent officer.		
	[Liability limitation ag				
			eement with Mr. Kazuyoshi Tachibana to limit his liability und		
			ect to the approval of his election as Director, the Company intends	s to continue the	
	agreement to limit his liability to the amount stipulated by laws and regulations.				

[Special notes regarding the candidate for Director] There are no special interests between Mr. Kazuyoshi Tachibana and the Company.

No.	Name (Date of birth)	Past experience, positions, responsibilities and significant concurrent positions		Number of shares of the Company held
10	Kozo Machiya (January 17, 1958) New election	October 1985 December 2008 December 2012 August 2014 December 2014 December 2016 December 2018 June 2020	Joined the Company Licensing Manager of Research & Development Strategy Promotion Dept., Research & Development Division Exploratory Manager of Research Center, Research & Development Division General Manager of Research & Development Strategy Promotion Dept., Research & Development Division Executive Officer, General Manager of Research & Development Strategy Promotion Dept., Research & Development Strategy Promotion Dept., Research & Development Division Executive Officer, Deputy Division Manager of Research Division and General Manager of Research Center, Research Division and Exploratory Manager of Research Center, Research Division Senior Executive Officer, Division Manager of Research Division	7,998
[Reason for election as a candidate for Director]				
	-		nce drug discovering capability as head of the research segment	· ·
			he Board of Directors by drawing on these experiences and achieve	ements.
	[Special notes regardi	•		
	There are no special interests between Mr. Kozo Machiya and the Company.			

(Note) To secure talented personnel and support proactive and bold business decision making toward growth, the Company plans to renew a directors and officers liability insurance contract in December 2021, an outline of which is provided below. Of the Directors nominated in this Proposal, those nominated for reelection are already insured under said contract, and will continue to be insured upon reelection. Additionally, new candidates will be insured under the contract after their election.

[Outline of content of directors and officers liability insurance contract]

(1) Actual ratio of premiums paid by the insured

Premiums, including riders, are paid by the Company, and the insured do not bear the actual premiums.

(2) Outline of events insured against

The policy, together with riders, will cover damages and legal fees, etc., that may arise due to the insured directors and officers assuming liability for the execution of duties or receiving a claim related to the pursuit of such liability. However, there are certain exemptions, such as in case of actions taken with the knowledge that such actions are in violation of laws and regulations.

(3) Measures to ensure that the appropriateness of directors' and officers' duties are not impaired The insurance contract contains stipulations regarding the amount of exemptions, and damages up to said exemption amount will not be covered. (Reference)

Independence Standards for Appointment of Independent Officers

- 1. In order to serve as an independent officer of the Company, he/she shall not fall under any of the following categories of persons.
 - (1) A person who is an executive director, executive officer, manager, or other employee (hereinafter collectively referred to as an "Executive Director, etc.") of the Company or any of its subsidiaries, or a person who was an Executive Director, etc., of the Company during the past 10 years prior to assuming the office of independent officer (if the person has, at any time during those past 10 years, served as a non-executive director [meaning a director who does not fall under the criteria of an executive director; hereinafter the same shall apply], audit & supervisory board member or accounting advisor of the Company or any of its subsidiaries, during the past 10 years prior to assuming the office of such position).
 - (2) A major shareholder of the Company (meaning a shareholder holding 10% or more of the voting rights; hereinafter the same shall apply). If such major shareholder is a corporation, a person who is an executive director, executive officer, corporate officer, manager or other employee of such corporation, or the parent company or any of the major subsidiaries of such corporation (hereinafter collectively referred to as an "Executive Person"), or an Executive Person thereof during the last three years.
 - (3) A person whose major business partner is the Company or any of its subsidiaries (meaning a person who received payment equivalent to 2% or more of the Company's consolidated annual sales for the most recent fiscal year from the Company or any of its subsidiaries; hereinafter the same shall apply). If such person is a corporation, a person who is an Executive Person of such corporation, or has been an Executive Person at any time during the three fiscal years prior to the most recent fiscal year.
 - (4) A major business partner of the Company (meaning a person who made payments equivalent to 2% or more of the Company's consolidated annual sales for the most recent fiscal year to the Company; hereinafter the same shall apply). If such person is a corporation, a person who is an Executive Person of such corporation, or has been an Executive Person at any time during the three fiscal years prior to the most recent fiscal year.
 - (5) A person who is a director (limited to those who are responsible for the business execution) of an organization (for example, public interest incorporated foundation, public interest incorporated association, non-profit corporation, etc.), which received donations or grants exceeding ¥10 million per year on average over the past three fiscal years, from the Company or any of its subsidiaries, or a person who is an officer, corporate member or employee who executes business of such organization.
 - (6) A person who is an Executive Person of a corporation which has accepted director(s) (either full-time or part-time) from the Company or any of its subsidiaries, or of the parent company or any of the subsidiaries of such corporation.
 - (7) A person who is an Executive Person, or has been an Executive Person in the last three years, of a financial institution or other major creditor (hereinafter referred to as a "Major creditor, etc.") that is essential to the Company's financing and is relied upon by the Company to the extent that there is no substitute, or the parent company or any of major subsidiaries of such major creditor, etc.
 - (8) A person who is currently an accounting auditor, certified public accountant (or tax accountant) who serves as accounting advisor, or a member, partner or employee of an auditing firm (or tax accountant office) for the Company or any of its subsidiaries.

- (9) A person who has been an accounting auditor, certified public accountant (or tax accountant) who served as accounting advisor, or a member, partner or employee of an auditing firm (or tax accountant office) who has actually engaged in the auditing operations (excluding assisting involvement) for the Company or any of its subsidiaries over the last three years (including those who are currently retired from or have left the relevant organization).
- (10) A person who is an attorney-at-law, certified public accountant, tax accountant or any other consultant that does not fall under items (8) or (9) above, and has received monetary or any other financial benefits of ¥10 million or more per year on average over the past three years, in addition to directors' remuneration, from the Company or any of its subsidiaries.
- (11) A person who is a member, partner, associate or employee of a law firm, audit firm, tax accountant office, consulting firm or any other professional advisory firm which does not fall under items (8) or (9) above, and has received payment of ¥10 million or more per year on average over the past three years, from the Company or any of its subsidiaries.
- (12) Any person who was an Executive Person, non-executive director or audit & supervisory board member of the parent of the Company in the period of 10 years prior to his/her appointment.
- (13) Any person who is, or was in the last 10 years, an Executive Person in a sister company of the Company (a company that has the same parent as the Company).
- (14) A spouse, a relative within the second degree, or a relative living in the same household of the person listed hereunder.
 - A. Person listed above
 - B. Executive Person, non-executive director, accounting advisor or audit & supervisory board member of the parent of the Company
- 2. In order to serve as an independent officer of the Company, it is required that he/she be free from risk of developing a substantive conflict of interest on a constant basis with the Company's general shareholders for reasons other than those covered by Paragraph 1 above.
- 3. Even if he/she falls under any of the categories set forth in Paragraph 1 above, when the Company believes that the individual is appropriate to be appointed as an independent officer of the Company based upon his/her personal quality and insight, it may appoint such individual as an independent officer on the condition that it explains to the public that he/she satisfies the requirements for outside director set forth by the Companies Act, and provides reasons why it considers he/she be appropriate for its independent officer.

Business Report

(April 1, 2020 - March 31, 2021)

I. Overview of the corporate group

The Company changed its accounting closing date from September 30 to March 31 by resolution of the 120th Ordinary General Meeting of Shareholders held on December 20, 2019.

Accordingly, the previous fiscal year was a six month-period from October 1, 2019 to March 31, 2020 and therefore, please note that comparisons with the previous fiscal year are not stated in this business report for the fiscal year under review.

1. Business progress and results

During the fiscal year under review, Japan's economy remained in a severe situation due mainly to a decrease in corporate earnings, weak consumer spending and a worsening employment environment caused by the spread of COVID-19. Although production activities and capital spending of companies currently show a recovery trend, economic prospects are still uncertain since the number of infected persons again turned to an increasing trend with increasing variants of the COVID-19.

In the environment surrounding agriculture, farm production is expected to continue growing since demand for agricultural products will expand on the background of an increasing global population and economic development of emerging markets. The agrochemical market worldwide is returning to an upward trend thanks to increasing demand in the Americas and other regions despite slower growth for the past few years. Looking at sales territories of the Group, the agrochemical market in North America has remained steady, benefiting from good weather. In Central and South America, demand has grown in Brazil thanks to expanded soy bean and maize planted areas and other factors. In Asia, demand has grown in China where mild weather continued and India which benefitted from abundant monsoon rain. On the contrary in Europe, the overall market experienced stagnant growth affected by bad weather and distribution inventories in the past years.

In domestic agriculture, structural problems such as an aging population of agricultural workers, a worsening shortage of successors and increasing abandoned farmland continue to remain unsolved. For addressing these problems, the Headquarters on Creating Dynamism through Agriculture, Forestry and Fishery Industries and Local Communities under the national government is having discussions about improving productivity through implementation of smart agriculture that utilizes robotics technologies, ICT, etc. Also, the Green Food System Strategy has been formulated as a policy to achieve both improvement of productivity and sustainability of food, agriculture, forestry and fisheries through innovation. Since this policy considers measures for reducing the volume of chemical pesticides used (risk conversion), its impact on the domestic agrochemical business should be monitored.

The Group's agrochemical business has a social mission that it contributes to a safe and stable food supply worldwide. To fulfill this mission, though amid the COVID-19 pandemic, the Group is making efforts to maintain a stable supply of agrochemical products to consumers.

Under such circumstances, the Group has executed the "Ensuring Growing Global 2021 (EGG2021)" medium-term management plan, aiming to improve profitability and strengthen the power of the Group. Net sales of the Group amounted to 71,525 million yen for the fiscal year under review. In terms of profits, operating profit and ordinary profit amounted to 6,981 million yen and 5,722 million yen, respectively and profit attributable to owners of parent amounted to 4,344 million yen.

An overview of each business segment is as follows:

(1) Agrochemical business

Regarding agrochemical sales in Japan, the Group has struggled to spread our core internally developed products such as tiadinil, a fungicide for paddy rice (product name: V-GET) and fungicide pyraziflumid for horticultural use (product name: "Parade") while expanding sales of these products. In addition, since the Group leveled out sales according to seasons of pesticide use and actual distribution through improvement of the business practice from the previous fiscal year, net sales increased. Meanwhile, for the smartphone application "Leime AI Disease, Pest & Weed Analysis" distributed by the Company from April 2020, cabbages, lettuces, napa cabbages, broccoli and leeks were newly added to diagnosed crops, in addition to existing paddy rice, in January 2021 and thus convenience for producers has been enhanced through the smart agriculture.

For overseas agrochemical sales, although the demand is on upward trend in Brazil which is the world largest agrochemical market, Sipcam Nichino Brasil S.A. experienced stagnant sales growth due mainly to intensifying competition. On the other hand, in North America, Nichino America, Inc. saw growth of net sales driven by sales of the insecticide buprofezin of which technology diffusion activity effectively worked and the fungicide flutolanil of which demand increased thanks to expansion of peanut acreage. Also, net sales of Nichino India Pvt. Ltd. in India increased due to good monsoon rain as well as contribution from the tolfenpyrad insecticide for horticultural use and the insecticide flubendiamide, sales of which started from the current fiscal year. Furthermore, in Europe, net sales of Nichino Europe Co., Ltd. increased due mainly to increased sales of the potato desiccant pyraflufen-ethyl which took away shares from competing products.

Expertise and technological fee revenue decreased due mainly to stagnant sales growth of customers to which the technology is licensed out.

As a result of the above, net sales of the agrochemical business amounted to 65,386 million yen and operating profit amounted to 5,998 million yen.

(2) Chemicals other than agrochemicals business

In the chemicals business, AgriMart Corporation experienced stagnant sales growth of termiticides due mainly to a decrease in housing starts. On the other hand, in the pharmaceutical business, net sales of the athlete's foot segment including the topical antifungal drugs luliconazole and lanoconazole increased.

As a result of the above, net sales of the chemicals other than agrochemicals business amounted to 4,279 million yen and operating profit amounted to 1,470 million yen.

Business	Net sales	Composition
Agrochemical business	65,386 million yen	91.4%
Chemicals other than agrochemicals business	4,279 million yen	6.0%
Other business	1,859 million yen	2.6%

2. Research and development activities

(1) Research activities

During the fiscal year under review, as the final fiscal year of the "Ensuring Growing Global 2021 (EGG2021)" medium-term management plan, the Company worked to enrich and step up pipeline compounds and create new lead compounds in exploratory research, in an effort to create new chemicals in a sustainable manner. Additionally, in research and development, the Company promoted strategic and global research activities through cooperation between group companies, working to maximize development of new chemicals and maintaining and expanding the performance of existing chemicals. 1) Creation of new compounds

With the goal of "launching one agent every three years," the Company qualitatively and quantitatively improved exploratory research by unifying the three segments of chemistry, biology, and safety, while advancing diverse medicine creation through open innovation with universities and public research institutions, etc. Among these, for several promising candidate compounds, the Company made steady progress toward development. Furthermore, new compounds were also discovered to serve as seeds for future pipeline enrichment. Meanwhile, the Company worked to expand initiatives in the research sector for animal health care products and pharmaceuticals in an effort to strengthen the life sciences field, and promoted research in this field.

2) Promotion of new chemical development and maintaining and expanding existing chemicals

By strengthening global cooperation among group companies, the Company strategically advanced performance evaluations and information sharing to develop new chemicals and maintain and expand existing chemicals, while also considering cost reductions for ingredients in an effort to improve profitability. Application research was diligently pursued for the launch of benzpyrimoxan (product name: "Orchestra"), a novel insecticide for paddy rice.

3) Promoting consideration of new businesses

The Company is accumulating implementation effectiveness data for the full-scale sale of a frost damage prevention chemical that makes use of supercooling acceleration substances. Considerations are also underway in cooperation with external institutions for evaluating other new business themes from a technical perspective and establishing business models.

(2) Development activities

In December 2016, to maximize the value of the Company's intellectual property in response to a rapidly changing market environment, the Market Development Division was established as a new organization integrating the Marketing Department, Development Department, and Registration Department, with the mission of pursuing the development and discovery of new markets. During the current fiscal year, the final year of the EGG2021 medium-term management plan, the Company has been developing the above measures and promoting growth strategies.

1) Newly developed products

Benzpyrimoxan, a novel insecticide for paddy rice for which joint development has been ongoing simultaneously in Japan and India, has been developed concurrently in the two countries in collaboration with Nichino India Pvt. Ltd., and registration applications were completed in Japan and India in February 2019. Its novel effects were highly rated in Japan, and after application of the priority evaluation system, Orchestra Flowable and Orchestra Dust Formulation acquired agrochemical registration ahead of schedule in September 2020. Sales of Orchestra Flowable began in May 2021. Registration is projected to be acquired in India in 2022, and the Company plans to submit an application for import tolerance to the United States in 2021.

Furthermore, the Company is considering the development of two insecticides and one fungicide as new chemical pipelines.

For the novel general fungicide pyraziflumid (product name: "Parade"), the Company sells Parade 15 Flowable for fruit trees, Parade 20 Flowable for vegetables, and Decide Flowable for turf. The Company promoted Parade 20 Flowable for applications in a new treatment field (cell seedling irrigation treatment) and acquired new registration for use in leeks, in addition to lettuce, napa cabbage, and cabbage. Global development of this chemical is also underway, acquiring chemical registration in South Korea in March 2019 and beginning sales of the product in 2020 in cooperation with a local sales company. Application for registration in the United States (including California), Canada, and Mexico were filed in 2019, and registration and beginning of sales are expected in 2022. The Company is also considering possibilities for development in Europe, Brazil, and other countries and regions. 2) New domestic products

With the objective of enriching the domestic product portfolio, the Company began sales of tiadinil, a fungicide for paddy rice (domestic product name: V-GET), as V-GET Haco-ranger L Granule and Haco-guard Granule, which are box treatment agents for paddy rice that include a novel insecticide. For

other existing proprietary product lines, the Company is actively expanding applications for unmanned aerial dispersion via drones, etc., in the horticultural field, and registrations were acquired for the PHOENIX Water-Soluble Powder and AXEL Flowable for sweet potatoes.

Additionally, sales of Field Saver Granules began as a weed inhibitor for vegetation management.

Furthermore, the Company began test marketing a frost damage prevention chemical that makes use of supercooling acceleration substances (product name: Frost Buster), and is working with related segments and group companies to acquire knowledge for full-scale market launch.

3) Overseas products

Sales of the pyflubumide acaricide have already begun in South Korea and Jordan; registration has been acquired in Syria, and applications for registration have been filed in Vietnam and Israel. Evaluations are also ongoing to determine development possibilities in other countries and regions.

The pyrifluquinazon insecticide acquired registration for food use in the United States in November 2018 in collaboration with Nichino America Inc., and the product is now on the market for widespread sales. Furthermore, in addition to the existing markets of Mexico and Syria, sales began in Guatemala and Pakistan, and mixture registration was acquired in South Korea. Additionally, measures are being taken to steadily expand the number of countries and regions where it is registered, including applying for registration in China and developing a mixture in India.

Sales of the tolfenpyrad insecticide have begun in some regions of the United States, and registration has been acquired in California, the main market. In addition, registration was also acquired in Brazil, and sales are projected to begin during 2021. Furthermore, the Company has re-applied for registration in China, and is gradually expanding the number of countries and regions where it is registered.

Registration was acquired for flubendiamide in Brazil in 2020 in collaboration with Nichino Do Brasil Agroquimicos Ltda., and sales began in 2021.

Although over 40 years have passed since isoprothiolane was launched as a method to combat rice blast, development is progressing to expand its applications to include the banana sigatoka disease field, a completely new application, in Central and South America, the Philippines, and other regions. IT applications have also been filed to Europe and the United States, which are essential for business.

For orthosulfamuron, an herbicide acquired from ISEM based in Italy, the Company has acquired registration in the United States for its use in the field of fruit tree undergrowth weed control, separately from its use in the sugar cane ripening field. It is also continuing its consideration into the development of new mixtures and its activities to seek new possibilities for expansion into other fields, and worked to support its global sales expansion. Furthermore, preparations are underway for an additional application in the United States by Nichino India Pvt. Ltd. as a plant for manufacturing active ingredients.

The herbicide pyraflufen-ethyl has been reassessed in Europe and has been approved for registration until 2031. The Company will continue to register the formulation in various countries.

For the insecticide buprofezin, insecticide and acaricide fenpyroximate, and fungicide flutolanil, the Company is working to expand and maintain the business for each product by maintaining and expanding their registrations globally.

In jointly-developed products, the Company is cooperating with Bayer CropScience, the licensee for flubendiamide, and BASF, the licensee for metaflumizone, in an effort to expand markets and sales globally. This has contributed to the Company's expertise and technological fee revenue.

To fulfill its responsibilities to society as a research and development-oriented company, the Company will continue to focus on launching new products that are considerate of the environment and safety through technological innovation, in compliance with the letter and the spirit of laws and regulations. Additionally, the Company will promote active global expansion under its new medium-term management plan, continuously creating new active ingredients that are cost-competitive, while strengthening revolutionary and well-planned activities in anticipation of the future market environment.

3. Status of capital investment

The total amount of capital investment for the fiscal year under review was 1,537 million yen, primarily comprising expenses associated with updating existing facilities at the Fukushima and Saga Plants.

4. Status of fund procurement

There were no matters of note during the fiscal year under review.

5. Status of business transfers to and from the Company

There were no matters of note during the fiscal year under review.

6. Status of stock holdings in other companies or acquisition or disposal of stock acquisition rights, etc. There were no matters of note during the fiscal year under review.

7. Medium to long term management strategy and issues to be addressed

The environment surrounding the agrochemical business, which is the Group's core business, is seeing an expansionary trend in the global agrochemical market, owing to heightened demand for food stemming from factors including an increasing global population and economic development in emerging markets. Meanwhile, in Japan, the agrochemical market is projected to continue on a declining trend against a backdrop of an aging population of agricultural workers, a decrease in farming land due to a worsening shortage of successors, and government policies that seek to reduce agricultural materials costs. Additionally, creating new chemicals is becoming increasingly complex and hurdles for registration of new agrochemicals are becoming stricter, leading to an increase in new chemical development cost and development time. Furthermore, increasingly strict requirements for agrochemical registration in various countries, price competition with generic agrochemicals, higher raw materials expenses and outsourced manufacturing expenses, and effects of irregular weather on agricultural products, etc., are creating an increasingly strict business environment for the Group.

In addition, concerning the future outlook, continuing from the previous fiscal year, the end of the spread of COVID-19 infection both within and outside Japan remains unpredictable, and there are concerns that the global economy will decelerate due to factors such as a deterioration in corporate earnings and the employment environment. As the agrochemical business, which is the Group's core business, is a business associated with the roots of agricultural products in its role supporting a safe and stable food supply, it can be thought that the effects will be limited relative to other industries, but there may be direct effects on production and procurement, or indirect effects due to changes in the agricultural environment.

Amid such a business environment and under the "Nichino Group - Growing Global to become an outstanding globally competitive group" Group Vision, during the fiscal year under review which served as the final fiscal year of the "Ensuring Growing Global 2021 (EGG2021)" medium-term management plan, the Group was able to achieve a certain level of results in strengthening its business foundations, including applying for registrations and promoting development for key chemicals in target markets, enriching the pipeline, strengthening sales structures in India, responding to smart agriculture, and promoting operational reforms and workstyle reforms. Additionally, activities were promoted to create and manifest synergies at an early stage from the capital and business alliance with ADEKA Corporation.

In "Ensuring Growing Global 2 (EGG2)," the new medium-term management plan that will begin from the year ending March 31, 2022, the Group will continue to maximize contributions to revenue from previous investments and M&A projects, while planning to aim to expand business content through progress in further growth strategies. In addition to achieving 6.4 billion yen in operating profit and 89.0 billion yen in net sales during the year ending March 31, 2024, the final fiscal year of the plan, the Group plans to expand business content through progress in further growth strategies, moving toward targeting net sales of 100.0 billion yen.

[Nichino Group Vision]

"Nichino Group - Growing Global"

- Supporting agricultural production and healthy lifestyles by providing advanced technologies that meet customer needs, such as new agrochemicals, pharmaceuticals, and animal health care products.
- Contributing to a sustainable society by expanding products and services that contribute to the SDGs, such as products with low environmental impact and labor-saving technologies.

[Medium-term management plan (Year ending March 31, 2022 to year ending March 31, 2024)]

1) Name: "Ensuring Growing Global 2 (EGG2)"

2) Numerical plans

	Year ending
	March 31, 2024 plan
	(Final fiscal year)
	89.0 billion yen
Consolidated net sales	(Target net sales:
	100.0 billion yen)
Operating profit	6.4 billion yen
Overseas net sales	57.1 billion yen
Overseas net sales ratio	64%

(Note) The planned figures, earnings forecasts, and other forward-looking statements indicated in this document are based on currently available information as well as certain assumptions that the Company deems to be reasonable but actual earnings may differ significantly due to various factors.

3) Basic policy

Toward achievement of the Group Vision, the Company has established the new corporate statement of "Global Innovator for Crop & Life" to strengthen foundations for creating a robust global structure, continuing the initiatives of the previous medium-term management plan. To strengthen foundations, in addition to improving profitability through expanding group synergies, the Company will have a basic policy of innovating technologies, establishing next-generation businesses, and sustainably improving corporate value, supporting agricultural production and healthy lifestyles via advanced technologies and aiming to become a corporate group that can contribute to a sustainable society.

i) Improve profitability

- Expansion of priority products
- · Cost reduction through optimal active ingredient manufacturing system
- · Expansion of group synergy

ii) Technological innovation and establishment of next-generation businesses

- · Promotion and global expansion of research and development
- Expansion of non agrochemical areas
- DX initiatives

iii) Sustainable growth in corporate value

- · Strengthening CSR activities and ESG management
- Promotion of business reform and work style reform

Specifically, the Company will steadily implement the following measures.

<Expansion of priority products>

By defining benzpyrimoxan, pyrifluquinazon, pyraflufen-ethyl, and flubendiamide as priority products, the Company will work to expand sales areas and promote sales through simultaneous development within and outside Japan and promoting acquisition of overseas registrations. Additionally, by defining Brazil and India as primary strategic areas, the Company will expand its business scale with overseas group companies as growth drivers.

<Cost reduction through optimal active ingredient manufacturing system>

Establishing the optimal global production system of active ingredients and reducing costs, the Company will aim to improve efficiency of production through smart factories. <Expansion of group synergy>

Various measures that will lead to stronger sales expansion will be steadily implemented by business divisions and group companies. The Company will also ascertain dealer sales and inventory levels to work toward timely product selection and sales campaign support.

<Promotion and global expansion of research and development>

As difficulty in creating new chemicals increases, steady progress is being made in enriching pipeline compounds. The Company will realize early stage development of such compounds. Additionally, for new chemical currently under development, by continuing with strategic research and development expense

investment (about 10% of net sales), the Company will steadily proceed toward commercialization. By strengthening global registration and development capabilities, the Company will strengthen cooperation within the Group with the objective of optimal commercialization.

<Expansion of non agrochemical areas>

Through applying technologies and experience gained in the agrochemical business, the Company will provide new value to society that will contribute to healthy lifestyles via the life sciences, including development of pharmaceuticals and animal health care products, introduction of biotic pesticides and biostimulants that will aid in healthy plant growth, businesses that make use of half-fermented production technologies using natural ingredients, and creating crops that contain specified functional components. The Company will also consider business expansion through M&A and incorporating external value, etc., as opportunities arise.

<DX initiatives>

Beginning with the promotion of energy efficiency through smart agriculture, the Company will promote transfer to smart factories, and make use of social networking services and webinars in its promotion activities, using digital and IT technologies to work toward improving customer service and corporate value by innovating in business and operational ideals.

<Strengthening CSR activities and ESG management>

With a basic policy of "Contributing to food, the environment, and society through technological innovation," the Company will engage in the seven priority issues of enriching compliance and risk management, raising the level of environmental management, enriching human rights management, promoting a corporate culture of safety, development of technologies and products in response to societal needs, participation in communities, and strengthening corporate and organizational governance. To steadily implement these issues, the Company will strengthen CSR management via measures including strengthening corporate governance, promoting diversity management, and positioning the CSR Committee on the same level as the Management Committee to further improve the CSR activities of the Group.

<Promotion of business reform and work style reform>

The Company will increase employee motivation by fundamentally revising existing structures in areas such as personnel appraisal systems and work benefits, in addition to establishing an office environment where employees can work regardless of the time and place, creating a work environment that improves productivity of employees from both soft and hard perspectives. Furthermore, by strengthening measures in diversity and inclusion, the Company will promote personnel development of employees that can work on the global stage.

4) Dividend policy

The Company aims dividend payout ratio of 30% or more under a basic policy of a stable dividend payment.

The Group will further develop technologies that it has gained in the agrochemical business, continuously provide advanced technologies in new agricultural, pharmaceutical, and animal health care products, and contribute to society by supporting agricultural production and healthy living. Aiming to become a corporate group that contributes to the future of humanity, the Group will expand business activities as a research and development-oriented company that fulfills its social responsibilities in strict compliance with laws and regulations.

The Company thanks shareholders for their continued support.

8. Trends in assets and income

Item	Fiscal year ended September 30, 2018 119th fiscal year	Fiscal year ended September 30, 2019 120th fiscal year	Fiscal year ended March 31, 2020 121st fiscal year	Fiscal year ended March 31, 2021 122nd fiscal year (Fiscal year under review)
Net sales	61,213 million yen	63,260 million yen	35,674 million yen	71,525 million yen
Ordinary profit	3,651 million yen	2,984 million yen	4,004 million yen	5,722million yen
Profit attributable to owners of parent	2,507 million yen	2,684 million yen	1,477 million yen	4,344 million yen
Earnings per share	37.46 yen	34.07 yen	18.75 yen	55.23 yen
Total assets	98,003 million yen	94,464 million yen	102,214 million yen	107,969 million yen
Net assets	57,576 million yen	58,198 million yen	58,372 million yen	62,071 million yen
Net assets per share	706.59 yen	713.99 yen	716.47 yen	774.76 yen

(Notes) 1. Earnings per share is calculated based on the average number of outstanding shares during the period, excluding treasury shares.

2. Net assets per share is calculated based on number of outstanding shares at the end of the period, excluding treasury shares.

- 3. The "Partial Amendments to Accounting Standard for Tax Effect Accounting" (ASBJ Statement No. 28; February 16, 2018) have been applied from the beginning of the 120th fiscal year, and figures, etc., for the 119th fiscal year are figures, etc., after retrospective application of said accounting standard.
- 4. The 121st fiscal year is the six-month period from October 1, 2019 to March 31, 2020, due to a change in the closing date.

9. Status of significant parent companies and subsidiaries

(1) Relationship with parent company

Status of parent company

The Company's parent company is ADEKA Corporation, and said company holds 40,176 thousand shares (voting rights ratio: 51.5%) of the Company's shares, including indirect holdings.

The Company has received two concurrently serving officers from the parent company.

The Company has concluded a capital and business alliance agreement with the parent company. An overview is as follows.

1) Objective

While maintaining the independence of the Company's management in principle, the Company and the parent company will cooperate via the capital and business alliance between the two companies, executing and promoting strategic plans and activities concerning the life sciences business beginning with the Company's agrochemical business, with the objective of maximizing the corporate value of both companies.

2) Maintaining listing and maintaining company name

As a basic policy, the parent company and the Company will maintain the Company's listing on the First Section of the Tokyo Stock Exchange and maintain the Company's name of NIHON NOHYAKU CO., LTD.

3) Right to designate officers

Upon deliberation with the Representative Director (excluding Director designated by the parent company) of the Company, the parent company has the right to designate Directors of the Company (Either Directors serving as the Audit & Supervisory Committee Members or other Directors is irrelevant, and the ratio of persons designated as each is also irrelevant. Of which, one shall be a Representative Director. Additionally, if the parent company designates eight Directors, one must be an Independent Outside Director.), in a number determined by multiplying 16 by the ratio of voting rights held by the parent company (However, the upper limit shall be eight. Additionally, numbers less than one shall be rounded down.). Furthermore, the number of Directors of the Company who are not Directors serving as the Audit & Supervisory Committee Members will be 11 or less, and the number of Directors serving as the Audit & Supervisory Committee Members will be 5 or less. However, this may change if advance written approval is obtained from the parent company.

Excluding cases where advance written approval is obtained from the parent company, the Company will not issue, dispose of, or grant shares, etc. (Defined as rights to acquire the Company's shares, stock acquisition rights, option rights, share transfer rights, or any other shares of the Company.), and if such

an issuance, etc., is to be conducted, the parent company has the right to receive a number of shares, etc., required to maintain the voting rights ratio of the tender offeror as of the time immediately before said issuance, etc., is to be conducted at a price identical to the paid-in amount or exercise price of the shares, etc., concerning said issuance, etc.

5) Content of business alliance

To achieve the goals of this capital and business alliance agreement, etc., the tender offeror and the Company will conduct a business alliance with the following content, and specific content shall be determined via deliberation between both companies.

- (i) Improve development speed through mutual support in the research and development sector
 - (a) Strengthen life sciences field
 - (b) Use compounds database
- (ii) Improve productivity through mutual use of production technologies and process chemistry
- (iii) Expand sales channels through mutual use of global networks
- (iv) Develop highly functional compounds by providing technologies in synthesis reactions, distributed technologies, and analysis technologies, etc.
- (v) Exchange of researchers with knowledge in various fields
- 6) Termination of this capital and business alliance agreement

This capital and business alliance agreement will be terminated under certain conditions, such as if both parties agree in writing to terminate this agreement.

In addition, the Company has agreed with the parent company about having prior consultation with the parent company and holding meetings for prior explanation and discussion concerning important matters to be resolved by the Company's Board of Directors which may have significant influence on management and results of the entire group of the parent company, from a perspective of balancing control of the group companies by the parent company and independence of the Company's decision making.

Company name	Capital	The Company's investment percentage	Principal business
Nichino Ryokka Co., Ltd.	160 million yen	100.0%	Construction, design, contracting, and supervision of greenification gardens, etc., and sales of chemicals/pesticides for gardens and greenification, etc.
Nichino Service Co., Ltd.	3,400 million yen	100.0%	Production, order receipt, storage, and transport of agrochemicals, real estate leasing and management, and warehousing, etc.
Nichino America, Inc.	700 thousand U.S. dollars	100.0%	Production, development, and sales of agrochemicals in the United States, etc.
Nihon Ecotech Co., Ltd.	20 million yen	100.0%	Analysis of agrochemical residue, safety testing of chemical substances, consulting regarding environmental safety, etc.
Taiwan Nihon Nohyaku Co., Ltd.	40 million NT dollars	57.0%	Development, promotion, and sales of agrochemicals in Taiwan, etc.
AgriMart Corporation	50 million yen	100.0%	Sales of termite control agents/devices, pest control agents/devices, etc.
Nichino India Pvt. Ltd.	3 million rupees	99.9% (100.0%)	Production, development, and sales of agrochemicals in India, etc.
Sipcam Nichino Brasil S.A.	223 million reals	50.0%	Production, promotion, and sales of agrochemicals in Brazil, etc.
Nichino Europe Co., Ltd.	30 thousand pounds	100.0%	Production, development, and sales of agrochemicals in Europe, etc.

(2) Material subsidiaries

(Notes) 1. The Company's investment percentage in parentheses is the ratio including indirect holdings.

2. On March 31, 2021, the Company made an additional acquisition of 6.0% of the outstanding shares of a consolidated subsidiary Taiwan Nihon Nohyaku Co., Ltd. As a result, the Company's investment percentage has become 57.0%, including the amount already acquired.

10. Principal business

Business	Main products
Agrochemical business	Insecticides, fungicides, insect-fungicides,
	herbicides, and active ingredients for agrochemicals
Chemicals other than agrochemicals business	Wood preservative agents, agricultural materials,
	turf-related products, pharmaceuticals, animal health
	care products, others
Other business	Greenification and gardening construction, etc.
	Real estate leasing, agrochemical logistics
	operations, warehousing, agrochemical residue
	analysis

11. Principal offices, research centers, and plants

(1)	Domestic	

Name	Location	Name	Location
Head office	Chuo-ku, Tokyo	Tokai-Hokuriku Sales Office	Osaka-shi, Osaka
Sapporo Branch	Sapporo-shi, Hokkaido	Fukuoka Branch	Fukuoka-shi, Fukuoka
Sendai Branch	Sendai-shi, Miyagi	Research Center	Kawachinagano-shi, Osaka
Tokyo Branch	Chuo-ku, Tokyo	Osaka Office	Osaka-shi, Osaka
Osaka Branch	Osaka-shi, Osaka		

(2) Domestic subsidiary offices (Plants)

Name	Location
Fukushima Plant, Nichino Service Co., Ltd.	Nihonmatsu-shi, Fukushima
Kashima Plant, same as above	Kamisu-shi, Ibaraki
Saga Plant, same as above	Miyaki-gun, Saga

(3) Overseas (including subsidiaries and affiliates)

Name	Location
Nichino America, Inc.	U.S.A. / Wilmington
Nichino Europe Co., Ltd.	UK / Cambridge
Nichino Shanghai Co., Ltd.	China / Shanghai
Taiwan Nihon Nohyaku Co., Ltd.	Taiwan / Taipei
Agricultural Chemicals (Malaysia) Sdn. Bhd.	Malaysia / Penang
Nichino Do Brasil Agroquimicos Ltda.	Brazil / Sao Paulo
Sipcam Nichino Brasil S.A.	Brazil / Uberaba
Nichino India Pvt. Ltd.	India / Hyderabad
Nichino Chemical India Pvt. Ltd.	India / Hyderabad
Sipcam Europe S.p.A.	Italy / Milan
Nichino Vietnam Co., Ltd.	Vietnam / Ho Chi Minh
Nihon Nohyaku Andica S.A.S.	Colombia / Bogota

12. Employees

Number of employees	Compared to previous fiscal year-end	
1,484 persons	Increase of 33 persons	
(NI-ta) The shear much as a fermiliar and descent in the de 204 measures and an termination of the second		

(Note) The above number of employees does not include 284 persons under temporary employment.

13. Major lenders

Name of lender	Outstanding loan balance (Millions of yen)
Mizuho Bank, Ltd.	7,094
The Norinchukin Bank	1,938
Banco do Brasil	1,650
MUFG Bank, Ltd.	1,475
Resona Bank, Limited.	1,271

II. Matters concerning status of the company (As of March 31, 2021)

1. Matters concerning shares

- (1) Total number of shares authorized to be issued
- (2) Total number of shares outstanding
- (3) Number of shareholders

199,529,000 shares 81,967,082 shares 11,500 persons (Increase of 115 persons compared to the previous fiscal year-end)

(4) Maior	shareho	Iders
		, wiajoi	Shareno	lucib

Shareholder name	Number of shares held (Thousand shares)	Shareholding ratio (%)
ADEKA Corporation	40,173	51.00
The Master Trust Bank of Japan, Ltd. (Trust account)	3,169	4.02
Mizuho Bank, Ltd.	1,997	2.54
Custody Bank of Japan, Ltd. (Trust account 9)	1,532	1.95
The Norinchukin Bank	1,401	1.78
Custody Bank of Japan, Ltd. (Trust account)	1,392	1.77
Asahi Mutual Life Insurance Company	853	1.08
Resona Bank, Limited.	719	0.91
DFA INTL SMALL CAP VALUE PORTFOLIO	559	0.71
Custody Bank of Japan, Ltd. (Trust account 5)	541	0.69

(Notes) 1. Although the Company holds 3,192 thousand shares of treasury shares, it is excluded from the above list of major shareholders.

2. The shareholding ratio is calculated after excluding treasury shares.

(5) Status of shares allotted to the Company's officers as consideration for execution of duties during the fiscal year under review

Category	Number of shares	Number of persons subject to allotment
Directors (excluding Directors serving as the Audit & Supervisory Committee Members and Outside Directors)	887 shares	1 person
Outside Directors (excluding Directors serving as the Audit & Supervisory Committee Members)	-	-
Directors serving as the Audit & Supervisory Committee Members	-	-
Audit & Supervisory Board Members	-	-

(6) Other important matters regarding shares Not applicable.

2. Matters concerning stock acquisition rights of the company

Not applicable.

3. Matters concerning officers of the company (1) Matters concerning Directors

3. Matters concerning (1) Matters concerning	g officers of the company	(As of March 31, 2021)
Name	Positions and responsibilities	Significant concurrent positions
Yosuke Tomoi	Representative Director, President	Significant concurrent positions
TOSUKE TOIHOI	Representative Director and Senior	
	Managing Executive Officer, Division	
Koji Shishido	Manager of Production Division, and in	
	charge of Environment Safety Dept.	
	Director and Managing Executive Officer,	
Hirofumi Tomita	in charge of Research Division, and	
Inforum Tomita	responsible for special missions	
	Director and Managing Executive Officer,	
	Division Manager of Administration	
	Division and responsible for Osaka Plant	
Hirohisa Yano	and General Manager of Osaka Plant, in	
	charge of Market Development Division,	
	and responsible for special missions	
	Director and Senior Executive Officer,	
	Division Manager of Industrial &	
Hiroshi Yamanoi	Pharmaceuticals Sales Division and General	
Throshi Tamanor	Manager of Pharmaceuticals Dept.,	
	Industrial & Pharmaceuticals Sales Division	
	Director and Senior Executive Officer, and	
	Division Manager of Domestic Sales	
Hideo Yamamoto	Division, General Manager of Smart	
	Agriculture Promotion Dept., Domestic	
	Sales Division	
	Director and Senior Executive Officer, and	
Hiroyuki Iwata	Division Manager of Corporate Planning	
5	Division	
		Advisor of ADEKA Corporation
Akio Kohri	Director	Outside Audit & Supervisory Board
		Member of Zeon Corporation
		Professor of Department of
Yasunori Matsui	Director	Business, College of Business,
		Rikkyo University
Kazuyoshi Tachibana	Director	
	Director	
Yoshiaki Higashino	Full-time Audit & Supervisory Committee	
	Member	
	Director	Representative Director and Senior
Haruhiko Tomiyasu	Audit & Supervisory Committee Member	Managing Operating Officer,
	Audit & Supervisory Committee Member	ADEKA Corporation
Iwao Toigawa	Director	Attornov at law
Twao Tolgawa	Audit & Supervisory Committee Member	Attorney-at-law
		Certified public accountant
		Certified public tax accountant
	Director	Representative Director of Nakata
Chizuko Nakata	Audit & Supervisory Committee Member	Business Consulting Co., Ltd.
	Audit & Supervisory Committee Wiember	Supervisory Director of Daiwa
		Securities Living Investment
		Corporation
Yoshiko Oshima	Director	Attorney-at-law
roshiko Oshilila	Audit & Supervisory Committee Member	Certified public tax accountant

(Notes) 1. Directors Mr. Yasunori Matsui, Mr. Kazuyoshi Tachibana, Mr. Iwao Toigawa, Ms. Chizuko Nakata, and Ms. Yoshiko Oshima are Outside Directors.

- 2. Mr. Yoshiaki Higashino has been selected as a Full-time Audit & Supervisory Committee Member to increase the effectiveness of information collection and other auditing processes and strengthen audit and supervisory functions.
- 3. The Company has designated Directors Mr. Yasunori Matsui, Mr. Kazuyoshi Tachibana, Mr. Iwao Toigawa, Ms. Chizuko Nakata, and Ms. Yoshiko Oshima as Independent Directors pursuant to the stipulations of the Tokyo Stock Exchange, and has notified the Exchange of said designation.
- 4. Full-time Audit & Supervisory Committee Member, Mr. Yoshiaki Higashino, has significant expertise in finance and accounting from serving as Division Manager of Administration Division of the Company.
- Audit & Supervisory Committee Member, Mr. Haruhiko Tomiyasu, is Representative Director and Senior Managing Operating Officer of ADEKA Corporation, and has significant expertise in finance and accounting from serving as the officer responsible for finance and accounting departments at said company.
- 6. Audit & Supervisory Committee Member, Ms. Chizuko Nakata, is a certified public accountant and certified public tax accountant, and has significant expertise in finance and accounting.
- 7. Audit & Supervisory Committee Member, Ms. Yoshiko Oshima, is an attorney-at-law and certified public tax accountant, and has significant expertise in finance and accounting.
- 8. ADEKA Corporation is the Company's parent company. Additionally, although the Company has purchasing and sales transactions with said company, the ratio of transactions within the Group is immaterial.
- 9. There are no other special relationships between companies at which Directors hold concurrent positions and the Company.
- 10. Outside Director, Mr. Yasunori Matsui retired from Professor of Department of Business, College of Business, Rikkyo University on March 31, 2021 and assumed office as Professor of Ohara Graduate School of Accounting on April 1, 2021.
- 11. Changes in positions and responsibilities after the end of the fiscal year under review are as follows.

	(As of April 1, 2021)
Name	Positions and responsibilities
Hiroshi Yamanoi	Director and Senior Executive Officer, and Division
	Manager of Industrial & Pharmaceuticals Sales Division
Hideo Yamamoto	Director and Senior Executive Officer, and Division
	Manager of Domestic Sales Division

(2) Outline of content of liability limitation agreements

The Company has concluded agreements to limit the liability for damages under Article 423, Paragraph 1 of the Companies Act with Directors Mr. Akio Kohri, Mr. Yasunori Matsui, Mr. Kazuyoshi Tachibana, Mr. Haruhiko Tomiyasu, Mr. Iwao Toigawa, Ms. Chizuko Nakata, and Ms. Yoshiko Oshima. The limit of liability for damages under said agreement is the limit stipulated by laws and regulations.

(3) Outline of content of directors and officers liability insurance contract

To secure talented personnel and support proactive and bold business decision making toward growth, the Company concluded a directors and officers liability insurance contract in December 2020, an outline of which is provided below.

1) Scope of the insured

Directors, Audit & Supervisory Committee Members and Executive Officers of the Company and directors and audit & supervisory board members of Nichino Ryokka Co., Ltd., Nichino Service Co., Ltd., Nihon Ecotech Co., Ltd. and AgriMart Corporation

2) Actual ratio of premiums paid by the insured

Premiums, excluding riders for shareholder lawsuits, are paid by the Company, and the said riders are paid by the insured.

3) Outline of events insured against

The policy, together with riders, will cover damages and legal fees, etc., that may arise due to the insured directors and officers assuming liability for the execution of duties or receiving a claim related to the pursuit of such liability. However, there are certain exemptions, such as in case of actions taken with the knowledge that such actions are in violation of laws and regulations.

4) Measures to ensure that the appropriateness of directors' and officers' duties are not impaired The insurance contract contains stipulations regarding the amount of exemptions, and damages up to said exemption amount will not be covered.

- (4) Remuneration, etc., for Directors and Audit & Supervisory Board Members for the fiscal year under review
 - 1) Matters regarding policies concerning determination of content of remuneration, etc., for individual Directors

Policies concerning determination of content of remuneration, etc., for individual Directors are determined at the Board of Directors after it receives opinions from the Governance Committee which is a voluntary advisory body of the Board of Directors on officers' remuneration. The overview of such policies are described below. In determination of content of remuneration for individual Directors, the Governance Committee makes an examination on the draft plan from various aspects such as consistency with such policies. Therefore, the Board of Directors basically considers that it is in line with such policies, respecting opinions from the Governance Committee.

- (i) Basic policy on remuneration, etc., for Directors (excluding Audit & Supervisory Committee Members)
- (a) Remuneration, etc., for Directors shall be connected with business results and the long-term interests of shareholders, while being appropriate, fair, and balanced to enable further desire to maximize sustainable corporate value and shareholder value.
- (b) Remuneration, etc., for Directors (excluding Audit & Supervisory Committee Members) shall have a basic structure consisting of basic remuneration and bonuses, and for Executive Directors, in addition to the above, performance-linked stock-based remuneration shall be provided. Additionally, remuneration, etc., for Outside Directors and Non-executive Directors shall not include performance-linked components.
- (ii) Policy on amount of remuneration, etc., of basic remuneration for individual Directors, timing of allotment, and determining conditions

Basic remuneration for Directors (excluding Audit & Supervisory Committee Members) shall be fixed monthly remuneration in cash. Basic remuneration for Executive Directors shall be determined based on duties and positions of business execution for Executive Directors, and based on responsibilities and whether or not the person serves full-time for Outside Directors and Non-executive Directors. Additionally, regarding Executive Directors, targets will be set for areas of responsibility after consultation with the Representative Director and President at the beginning of the fiscal year, and the level of achievement of said duties and business results will be reflected in remuneration for the following fiscal year. The Company shall strive to revise remuneration levels as appropriate in consideration of business results, standards at other companies, and social trends, etc.

(iii) Policy on amount of remuneration, etc., of bonuses for individual Directors, timing of allotment, and determining conditions

Bonuses for Directors (excluding Audit & Supervisory Committee Members) shall be allotted annually in cash at a certain time after the end of the fiscal year to which it applies. Bonuses for Directors (excluding Audit & Supervisory Committee Members) shall have the objective of increasing motivation to contribute toward improving business results for a single year. Similarly to fixed remuneration, the amount of bonuses for individual Executive Directors shall be determined by reflecting the level of achievement of duties and business results, and the amount of bonuses for Outside Directors and Non-executive Directors shall be allotted within the total amount of remuneration approved at a General Meeting of Shareholders.

(iv) Performance-linked stock-based remuneration

Performance-linked stock-based remuneration is a remuneration system for Directors (excluding Directors serving as the Audit & Supervisory Committee Members, Outside Directors, and Non-executive Directors) utilizing a share grant trust with the objective of furthering a sense of shared value with shareholders while increasing motivation for medium to long term improvement in business results and expanding corporate value. Under this system, a trust established and funded by the Company (hereinafter the "Share Grant Trust") acquires shares of the Company, and in accordance with the Share Grant Regulations established by the Company's Board of Directors, a number of shares of the Company equivalent to the number of points it has awarded each Director shall be granted through the Share Grant Trust at the time of the retirement of each Director, in principle.

Additionally, the applicable period for performance-linked stock-based remuneration shall be, in

principle, identical to the applicable period of the medium-term management plan, established every three fiscal years. Performance-linked stock-based remuneration is categorized into a fixed portion and a variable portion, and the performance-based index for variable portions shall be key performance indicators (KPIs) for the applicable medium-term management plan. Points for the fixed portion shall be granted at a certain time after the end of the fiscal year to which it applies. Points for the variable portion shall be granted at a certain time after the end of the medium-term management plan. If standard business results in the performance-based index are achieved, the ratio between the fixed portion and the variable portion of performance-linked stock-based remuneration for the applicable period shall be about 45:55. Points in the variable portion will vary within a range of 0% to 150% of the predefined standard amount, based on the level of achievement of business results of the performance-based index.

(v) Policy on determining ratio between amount of basic remuneration, amount of bonuses, and amount of performance-linked stock-based remuneration in amount of remuneration for individual Directors

The ratio of type of remuneration for Executive Directors shall be determined in consideration of factors including the Company's business characteristic that it is long-term research and development-oriented, the Director's position, duties, standards at other companies, and social trends. The ratio between basic remuneration, bonuses, and performance-linked stock-based remuneration during the period to which a medium-term management plan applies will be about 8:1:1.

(vi) Matters regarding procedures to determine content of remuneration, etc., for individual Directors (excluding Audit & Supervisory Committee Members)

Distribution of remuneration, etc., for individual Directors (excluding Audit & Supervisory Committee Members) shall be based on consultation with the Board of Directors, followed by an evaluation by the Governance Committee regarding factors including the duties, responsibilities, business results, and level of contribution in areas assigned to the Executive Director, after which reports are made regarding an increase or decrease in basic remuneration, total amount of bonuses to be granted, and content of distribution of bonus amounts.

The amount of remuneration, etc., for individual Directors (excluding Audit & Supervisory Committee Members) shall be entrusted to the Representative Director and President by resolution of the Board of Directors, and determined by the Representative Director and President based on reports from the Governance Committee. The content of the authority of the Representative Director and President is the amount of basic remuneration for each Director, the total amount of bonuses to be granted, and the distribution of the amount of bonuses.

Furthermore, performance-linked stock-based remuneration shall be determined in accordance with the Share Grant Regulations resolved by the Board of Directors.

2) Matters regarding resolution of the General Meeting of Shareholders concerning remuneration, etc., for Directors and Audit & Supervisory Board Members

The maximum annual aggregate amount of remuneration, etc., for Directors (excluding Audit & Supervisory Committee Members) was resolved to be 330 million yen (including the maximum annual aggregate amount of remuneration for Outside Directors of 30 million yen; excluding the portion of employees' salary) at the 121st Ordinary General Meeting of Shareholders held on June 26, 2020. The number of Directors (excluding Audit & Supervisory Committee Members) was 10 (including 2 Outside Directors) at the recess of said Ordinary General Meeting of Shareholders. Separately from said cash remuneration, the same Ordinary General Meeting of Shareholders resolved to allow Directors (excluding Directors serving as the Audit & Supervisory Committee Members, Outside Directors, and Non-executive Directors) to receive allotment of shares through a trust (hereinafter the "Trust") established and funded by the Company which acquires shares of the Company, and within a maximum aggregate amount of remuneration based on a performance-linked stock-based remuneration system in which the Company's shares are granted to each Director through the Trust according to the number of points granted to each Director. In principle, Directors will be granted the Company's stock at the time of retirement according to the number of points granted, and the resolution was made for the maximum aggregate amount of funding by the Company to be 75 million yen, and the maximum aggregate amount of points to be allotted to allottees to be 250,000 points (1 point is 1 share of the Company) for the applicable period (from the fiscal year ending on March 31, 2020 to the fiscal year ending on March 31, 2021 (18 months)). Additionally, a resolution was also made such that at the expiration of each applicable period, the Board of Directors may determine to extend the applicable period every three fiscal years, and if the trust period for the Trust is also extended, the Company may, during the applicable period of said extension as required additional funds for acquisition of the

Company's stock for allotment to Directors under the system, provide additional cash funding to the Trust in a maximum aggregate amount of 150 million yen for each applicable period of said extension, with the maximum aggregate amount of points to be granted to allottees to be 500,000. The number of Directors (excluding Directors serving as the Audit & Supervisory Committee Members, Outside Directors, and Non-executive Directors) as of the recess of said Ordinary General Meeting of Shareholders was seven.

The amount of remuneration, etc., for Directors serving as the Audit & Supervisory Committee Members was resolved to be a maximum annual aggregate amount of 60 million yen at the 121st Ordinary General Meeting of Shareholders held on June 26, 2020. The number of Directors serving as the Audit & Supervisory Committee Members at the recess of said Ordinary General Meeting of Shareholders was five.

The amount of remuneration for Audit & Supervisory Board Members was resolved to be a maximum annual aggregate amount of 60 million yen at the 95th Ordinary General Meeting of Shareholders held on December 20, 1994. The number of Audit & Supervisory Board Members at the conclusion of said Ordinary General Meeting of Shareholders was three.

3) Matters concerning entrustment of authority for determining content of remuneration, etc., for individual Directors

Based on the policy in "3. (4) 1) (vi) Matters regarding procedures to determine content of remuneration, etc., for individual Directors (excluding Audit & Supervisory Committee Members)" and pursuant to an entrustment resolution by the Board of Directors, Representative Director and President Yosuke Tomoi determines the specific content of remuneration for individual Directors.

The reason why said authority was transferred is because the Representative Director and President is the most suitable position to evaluate duties and performance achievements of each Director, watching the Company's current status from a higher perspective.

To ensure that said authority is appropriately exercised by the Representative Director and President, the Board of Directors has implemented measures such as consulting with the Governance Committee and receiving reports regarding an increase or decrease in basic remuneration, total amount of bonuses to be granted, and content of distribution of bonus amounts based on evaluations that contain the basic elements of assigned duties, responsibilities, business results, and level of contribution, etc., for Executive Directors, and as amounts of remuneration for individual Directors are determined after undergoing said procedures, the Board of Directors has judged that said contents are in line with the policy for determination.

4) Matters concerning performance-linked remuneration, etc.

By further clarifying the link between Director remuneration and the Company's business results and shareholder value and having Directors share the benefits and risks of fluctuations in share price with shareholders, the Company has introduced a performance-linked stock-based remuneration system for Directors (excluding Directors serving as the Audit & Supervisory Committee Members, Outside Directors, and Non-executive Directors), with the objective of increasing motivation to contribute to improving business results and expanding corporate value over the medium to long term.

The amount of performance-linked remuneration and the content of business results indices selected to serve as the basis for calculation for this system are the level of achievement of KPIs (consolidated operating profit and consolidated net sales for the final year of the medium-term management plan) of the medium-term management plan, and the reason that said business results indices were selected was to increase motivation for Directors to contribute to improving business results and expanding corporate value over the medium to long term.

Targets for business results indices selected to serve as the basis for calculation for the amount or number of performance-linked remuneration for this system in the fiscal year under review were consolidated operating profit of 4.7 billion yen and consolidated net sales of 76.3 billion yen for the fiscal year ended March 31, 2021, and the status of achievement is as shown in "Consolidated Statement of Income."

5) Total amounts, etc., of remuneration, etc., for Directors and Audit & Supervisory Board Members

	Total amount of	Total amount of remuneration, etc., by type (Millions of yen)			Number of
Officer category	remuneration, etc. (Millions of yen)	Basic remuneration	Bonuses	Noncash remuneration, etc.	applicable officers (Persons)
Directors (excluding Audit & Supervisory Committee Members) (Of which, Outside Directors)	260 (11)	206 (9)	21 (1)	32 (-)	12 (3)
Directors serving as the Audit & Supervisory Committee Members (Of which, Outside Directors)	35 (11)	30 (9)	5 (1)	-	5 (3)
Audit & Supervisory Board Members (Of which, Outside Audit & Supervisory Board Members	6 (1)	6 (1)	- (-)	-	4 (2)

(Notes) 1. The amount of bonuses above is the provision for bonuses for directors (and other officers) concerning the fiscal year under review.

- 2. Stock-based remuneration based on a performance-linked stock-based remuneration system is granted to Directors (excluding Directors serving as the Audit & Supervisory Committee Members, Outside Directors, and Non-executive Directors) as noncash remuneration. The content of said stock-based remuneration is as stated in "2) Matters regarding resolution of the General Meeting of Shareholders concerning remuneration, etc., for Directors and Audit & Supervisory Board Members" and the status of allotment is as stated in "1. Matters concerning shares."
- 3. The amount of noncash remuneration, etc., above is the provision for share awards concerning the fiscal year under review.
- 4. The Company shifted to a Company with an Audit & Supervisory Committee from a Company with an Audit & Supervisory Board at the recess of 121st Ordinary General Meeting held on June 26, 2020 (at the conclusion of deliberation on June 26, 2020).

(5) Matters concerning outside officers

1) Relationships between significant companies at which Company officers hold concurrent positions and the Company

As stated in "3. (1) Matters concerning Directors."

2) Status of key activities during the fiscal year under review

Name (Position)	Status of key activities
Yasunori Matsui	Mr. Yasunori Matsui has broad knowledge and insight in business
(Outside Director)	administration gained through many years of experience as a university professor (in accounting and business administration), and his expected role is to contribute to improving the effectiveness of the Company's Board of Directors by providing the Company with opinions and advice on the Company's overall management from an objective perspective. He has attended meetings such as the Board of Directors and Governance Committee meetings and expressed opinions in the form of appropriate advice and recommendations, etc. on overall management of the Company. He attended all 18 Board of Directors meetings held during the fiscal year under review.
Kazuyoshi Tachibana	Mr. Kazuyoshi Tachibana has a wealth of experience and broad-based
(Outside Director)	insight as operating officer of a listed company as well as manager of an overseas business entity, and his expected role is to contribute to improving the effectiveness of the Company's Board of Directors by providing the Company with opinions and advice on the Company's

	overall management from an objective perspective. He has attended
	meetings such as the Board of Directors and Governance Committee
	meetings and expressed opinions in the form of appropriate advice and
	recommendations, etc. based on deep insight as a manager.
	He attended all 16 Board of Directors meetings held after assuming
	office.
Iwao Toigawa	Mr. Iwao Toigawa has expertise as an attorney-at-law and wealth of
(Outside Director (Audit &	experience and broad knowledge of corporate legal affairs and his
Supervisory Committee	expected role is to strengthen the Company's audit functions, etc. and
Member))	contribute to improving the effectiveness of the Company's Board of
	Directors based on these insights. He has attended meetings such as the
	Board of Directors, Governance Committee and Compliance
	Committee meetings and expressed opinions in the form of appropriate
	advice and recommendations, etc., while performing audit duties and
	providing advice to ensure the appropriateness of the execution of
	Directors' duties.
	He attended all 18 Board of Directors meetings held during the fiscal
	year under review
	He attended all 8 Audit & Supervisory Committee meetings held during the fiscal year under review, and made comments as necessary to
	ensure highly effective audits.
Chizuko Nakata	Ms. Chizuko Nakata has deep insight in business administration as a
(Outside Director (Audit &	certified public accountant and certified public tax accountant and her
Supervisory Committee	expected roles is to strengthen the Company's audit functions, etc. and
Member))	contribute to improving the effectiveness of the Company's Board of
	Directors based on these insights. She has attended meetings such as
	the Board of Directors and Governance Committee meetings and
	expressed opinions in the form of appropriate advice and
	recommendations, etc., while performing audit duties and providing
	advice to ensure the appropriateness of the execution of Directors'
	duties.
	She attended all 18 Board of Directors meetings held during the fiscal
	year under review.
	She attended 7 of the 8 Audit & Supervisory Committee meetings held
	during the fiscal year under review, and made comments as necessary
	to ensure highly effective audits.
	Also, she attended all 2 Audit & Supervisory Board meetings held
	during the fiscal year under review, and made comments as necessary
N 11 01	to ensure highly effective audits.
Yoshiko Oshima	Ms. Yoshiko Oshima has expertise as an attorney-at-law and certified
(Outside Director (Audit &	public tax accountant and wealth of experience and broad knowledge of
Supervisory Committee Member))	corporate legal affairs and her expected roles is to strengthen the Company's audit functions, etc. and contribute to improving the
Weinber))	effectiveness of the Company's Board of Directors based on these
	insights. She has attended meetings such as the Board of Directors and
	Governance Committee meetings and expressed opinions in the form of
	appropriate advice and recommendations, etc., while performing audit
	duties and providing advice to ensure the appropriateness of the
	execution of Directors' duties.
	She attended all 18 Board of Directors meetings held during the fiscal
	year under review.
	She attended all 8 Audit & Supervisory Committee meetings held
	during the fiscal year under review, and made comments as necessary
	to ensure highly effective audits.
	Also, she attended all 2 Audit & Supervisory Board meetings held
	during the fiscal year under review, and made comments as necessary
	to ensure highly effective audits.
(Note) The Company shifte	ed to a Company with an Audit & Supervisory Committee from a

(Note) The Company shifted to a Company with an Audit & Supervisory Committee from a

Company with an Audit & Supervisory Board at the recess of 121st Ordinary General Meeting held on June 26, 2020 (at the conclusion of deliberation on June 26, 2020).

4. Matters concerning Accounting Auditor

- (1) Name of Accounting Auditor Kyowa Audit Corporation
- (2) Overview of content of liability limitation agreement Not applicable.

(3) Amount of remuneration, etc., for the Accounting Auditor during the fiscal year under review

Category	Amount paid
Amount of remuneration, etc., as Accounting Auditor for the fiscal year under review	37,000 thousand yen
Total amount of money and other property benefits payable by the Company and the Company's subsidiaries	39,400 thousand yen

- (Notes) 1. Under the audit agreement between the Company and Kyowa Audit Corporation, no clear distinction is made between the remuneration for audits pursuant to the Companies Act and that for audits pursuant to the Financial Instruments and Exchange Act, and since a substantial distinction cannot be made, the amount presented above is the total remuneration.
 - 2. Of the Company's significant subsidiaries, Nichino America, Inc., Taiwan Nihon Nohyaku Co., Ltd., Nichino India Pvt. Ltd., Sipcam Nichino Brasil S.A., and Nichino Europe Co., Ltd. receive audits from audit corporations other than the Company's Accounting Auditor.
- (4) Content of non-audit services Not applicable.
- (5) Matters concerning audits of subsidiaries Each of five consolidated subsidiaries of the Company is audited by an audit firm or other party other than the Company's Accounting Auditor.
- (6) Reasons the Audit & Supervisory Committee approved remuneration, etc., for the Accounting Auditor The Audit & Supervisory Committee of the Company, in consideration of the "Practical Guidelines on Cooperation with Accounting Auditors" published by the Japan Audit & Supervisory Board Members Association, confirmed the audit plan, status of audit implementation, and basis for calculation as shown in remuneration estimates of the Accounting Auditor, and upon consideration, agreed to the remuneration, etc., of the Accounting Auditor as prescribed under Article 399, Paragraph 3 of the Companies Act.
- (7) Policies for determining dismissal or non-reappointment of the Accounting Auditor

The Audit & Supervisory Committee of the Company shall determine the content of a proposal for the dismissal or non-reappointment of the Accounting Auditor to be submitted to a General Meeting of Shareholders if it has judged that it is necessary to do so, such as in cases where there are issues with the execution of duties by the Accounting Auditor.

Additionally, if the clauses of Article 340, Paragraph 1 of the Companies Act apply to the Accounting Auditor and it deems that there are no prospects of improvement, the Audit & Supervisory Committee shall dismiss the Accounting Auditor conditional upon the unanimous consent of all Audit & Supervisory Committee Members. In such case, an Audit & Supervisory Committee Member selected by the Audit & Supervisory Committee shall report the dismissal of the Accounting Auditor and the reason for it at the first General Meeting of Shareholders held following the dismissal.

(Note) Amounts and numbers of shares presented in this Business Report are rounded down to the nearest unit indicated.

Consolidated Balance Sheet

(As of March 31, 2021)

Description	Amount	Description	Amount
(Assets)		(Liabilities)	
Current assets	78,425	Current liabilities	35,323
Cash and deposits	19,278	Notes and accounts payable - trade	13,827
Notes and accounts receivable - trade	32,460	Electronically recorded obligations - operating	1,221
Electronically recorded monetary claims - operating	1,817	Short-term borrowings	10,901
Merchandise and finished goods	16,009	Current portion of bonds payable	193
Work in process	566	Accrued expenses	5,410
Raw materials and supplies	5,482	Income taxes payable	410
Other	2,990	Provision for bonuses	75
Allowance for doubtful accounts	(180)	Provision for bonuses for directors (and other officers)	42
Non-current assets	29,544	Provision for sales returns	3
Property, plant and equipment	14,651	Provision for environmental measures	50
Buildings and structures	4,449	Electronically recorded obligations - non-operating	4
Machinery, equipment and vehicles	3,567	Other	1,95
Land	5,906	Non-current liabilities	10,574
Construction in progress	64	Bonds payable	1,38
Other	663	Long-term borrowings	6,34
Intangible assets	4,119	Deferred tax liabilities	56
Goodwill	2,812	Provision for retirement benefits for directors (and other officers)	4
Software	464	Provision for share awards	50
Other	842	Retirement benefit liability	69
Investments and other assets	10,773	Other	1,492
Investment securities	5,805	Total liabilities	45,89
Deferred tax assets	1,103	(Net assets)	
Retirement benefit asset	1,903	Shareholders' equity	63,20
Other	2,308	Share capital	14,93
Allowance for doubtful accounts	(347)	Capital surplus	15,07
		Retained earnings	34,992
		Treasury shares	(1,80
		Accumulated other comprehensive income	(2,27
		Valuation difference on available-for-sale securities	893
		Foreign currency translation adjustment	(4,253
		Remeasurements of defined benefit plans	1,083
		Non-controlling interests	1,140
		Total net assets	62,07
Total assets	107,969	Total liabilities and net assets	107,96

Consolidated Statement of Income

(April 1, 2020 - March 31, 2021)

(Millions	of	yen)
-----------	----	------

Description	Amount
Net sales	71,525
Cost of sales	47,317
Gross profit	24,207
Selling, general and administrative expenses	17,225
Operating profit	6,981
Non-operating income	1,017
Interest and dividend income	173
Share of profit of entities accounted for using equity method	282
Gain on valuation of derivatives	275
Rental income from real estate	93
Other	192
Non-operating expenses	2,277
Interest expenses	458
Foreign exchange losses	1,598
Sales discounts	32
Other	187
Ordinary profit	5,722
Extraordinary income	1,689
Gain on sales of non-current assets	1,689
Extraordinary losses	1,561
Loss on disposal of non-current assets	53
Environmental expenses	1,498
Other	9
Profit before income taxes	5,850
Income taxes - current	1,537
Income taxes - deferred	288
Profit	4,024
Loss attributable to non-controlling interests	320
Profit attributable to owners of parent	4,344

Non-consolidated Balance Sheet

(As of March 31, 2021)

Description	Amount	Description	Amount
(Assets)		(Liabilities)	
Current assets	50,068	Current liabilities	19,216
Cash and deposits	10,227	Notes payable - trade	95
Notes receivable – trade	1,196	Accounts payable - trade	7,286
Accounts receivable - trade	19,913	Electronically recorded obligations - operating	1,221
Electronically recorded monetary claims - operating	1,806	Short-term borrowings	3,860
Merchandise and finished goods	11,070	Current portion of long-term borrowings	1,073
Work in process	551	Accounts payable - other	692
Raw materials and supplies	3,060	Accrued expenses	3,024
Prepaid expenses	322	Income taxes payable	177
Accounts receivable - other	1,263	Accrued business office tax	-
Consumption taxes receivable	363	Advances received	498
Short-term loans receivable	100	Provision for bonuses	446
Other	196	Provision for bonuses for directors (and other officers)	40
Allowance for doubtful accounts	(4)	Provision for sales returns	30
Non-current assets	36,938	Provision for environmental measures	508
Property, plant and equipment	11,290	Notes payable - facilities	11:
Buildings	3,048	Electronically recorded obligations - non-operating	4
Structures	527	Other	82
Machinery	2,320	Non-current liabilities	6,69
Vehicles	7	Long-term borrowings	5,25
Tools, furniture and fixtures	355	Long-term deposits received	864
Land	5,011	Provision for retirement benefits	300
Leased assets	17	Provision for share awards	50
Construction in progress	2	Deferred tax liabilities	29
Intangible assets	448	Other	190
Patent right	18	Total liabilities	25,913
Right to use facilities	12	(Net assets)	
Software	415	Shareholders' equity	60,19
Other	2	Share capital	14,93
Investments and other assets		Capital surplus	17,23
	25,199		
Investment securities	2,754	Legal capital surplus	12,23
Shares of subsidiaries and associates Investments in capital of subsidiaries and	18,756 210	Other capital surplus Retained earnings	5,000 29,82 0
associates Long-term loans receivable	2,520	-	1,574
Prepaid pension costs	647	Legal retained earnings Other retained earnings	28,25
Other	315	General reserve	3,145
Allowance for doubtful accounts	(4)	Retained earnings brought forward	25,100
		Treasury shares	(1,80
		Valuation and translation adjustments	89.
		Valuation difference on available-for-sale securities	893
		Total net assets	61,093
Total assets	87,007	Total liabilities and net assets	87,007

Non-consolidated Statement of Income

(April 1, 2020 - March 31, 2021)

(Millions	of	yen)
-----------	----	------

Description	Amount
Net sales	43,110
Cost of sales	28,860
Gross profit	14,249
Selling, general and administrative expenses	10,880
Operating profit	3,369
Non-operating income	641
Interest and dividend income	481
Other	160
Non-operating expenses	160
Interest expenses	71
Other	88
Ordinary profit	3,850
Extraordinary income	1,689
Gain on sales of non-current assets	1,689
Extraordinary losses	1,560
Loss on disposal of non-current assets	52
Environmental expenses	1,498
Other	9
Profit before income taxes	3,979
Income taxes - current	880
Income taxes - deferred	106
Profit	2,993

Accounting Auditor's Audit Report on the Consolidated Financial Statements (duplicated copy)

Independent Auditor's Report

(English Translation)

May 10, 2021

To the Board of Directors NIHON NOHYAKU CO., LTD.

Kyowa Audit Corporation Chiyoda-ku, Tokyo Masashige Takayama, CPA Representative Partner Engagement Partner Masashi Ozawa, CPA Representative Partner Engagement Partner

Opinion

Pursuant to Article 444, Paragraph 4 of the Companies Act, we have audited the accompanying consolidated financial statements, which comprise the consolidated balance sheet, the consolidated statement of income, the consolidated statement of changes in equity and the notes to the consolidated financial statements of NIHON NOHYAKU CO., LTD. (the "Company") for the fiscal year from April 1, 2020, through March 31, 2021.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position and results of operations of the corporate group, which consists of the Company and its consolidated subsidiaries, for the period covered by the consolidated financial statements in conformity with accounting principles generally accepted in Japan.

Basis for the Opinion

We conducted our audit in accordance with auditing standards generally accepted in Japan. Our responsibility under the auditing standards is stated in "Auditor's Responsibility for the Audit of the Consolidated Financial Statements." We are independent of the Company and its consolidated subsidiaries in accordance with the provisions related to professional ethics in Japan, and are fulfilling other ethical responsibilities as an auditor. We believe that we have obtained sufficient and appropriate audit evidence to provide a basis for our audit opinion.

Responsibilities of Management and the Audit & Supervisory Committee for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in Japan, and for designing and operating such internal control as management determines is necessary to enable the presentation and fair presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing whether it is appropriate to prepare the consolidated financial statements in accordance with the premise of a going concern, and for disclosing matters relating to going concern when it is required to do so in accordance with accounting principles generally accepted in Japan.

The Audit & Supervisory Committee is responsible for monitoring the execution of Directors' duties related to designing and operating the financial reporting process.

Auditor's Responsibility for the Audit of the Consolidated Financial Statements

Our responsibility is to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to express an opinion on the consolidated financial statements from an independent standpoint in an audit report, based on our audit. Misstatements can occur as a result of fraud or error, and are deemed material if they can be reasonably expected to, either individually or collectively, influence the decisions of users taken on the basis of the consolidated financial statements.

We make professional judgment in the audit process in accordance with auditing standards generally accepted in Japan, and perform the following while maintaining professional skepticism.

- Identify and assess the risks of material misstatement, whether due to fraud or error. Design and implement audit procedures to address the risks of material misstatement. The audit procedures shall be selected and applied as determined by the auditor. In addition, sufficient and appropriate audit evidence shall be obtained to provide a basis for the audit opinion.
- In making those risk assessments, the auditor considers internal control relevant to the entity's audit in order to design audit procedures that are appropriate in the circumstances, although the purpose of the audit of the consolidated financial statements is not to express an opinion on the effectiveness of the entity's internal control.
- Assess the appropriateness of accounting policies adopted by management and the method of their application, as well as the reasonableness of accounting estimates made by management and the adequacy of related notes.
- Determine whether it is appropriate for management to prepare the consolidated financial statements on the premise of a going concern and, based on the audit evidence obtained, determine whether there is a significant uncertainty in regard to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If there is a significant uncertainty concerning the premise of a going concern, the auditor is required to call attention to the notes to the consolidated financial statements in the audit report, or if the notes to the consolidated financial statements. While the conclusions of the auditor are based on the audit evidence obtained up to the date of the audit report, depending on future events or conditions, an entity may be unable to continue as a going concern.
- Besides assessing whether the presentation of and notes to the consolidated financial statements are in accordance with accounting principles generally accepted in Japan, assess the presentation, structure, and content of the consolidated financial statements including related notes, and whether the consolidated financial statements fairly present the transactions and accounting events on which they are based.
- Obtain sufficient and appropriate audit evidence regarding the financial information of the Company and its consolidated subsidiaries in order to express an opinion on the consolidated financial statements. The auditor is responsible for instructing, supervising, and implementing the audit of the consolidated financial statements, and is solely responsible for the audit opinion.

The auditor reports to the Audit & Supervisory Committee regarding the scope and timing of implementation of the planned audit, material audit findings including material weaknesses in internal control identified in the course of the audit, and other matters required under the auditing standards.

The auditor reports to the Audit & Supervisory Committee regarding the observance of provisions related to professional ethics in Japan as well as matters that are reasonably considered to have an impact on the auditor's independence and any safeguards that are in place to reduce or eliminate obstacles.

Interest

Our firm and engagement partners have no interests in the Company or its consolidated subsidiaries requiring disclosure under the provisions of the Certified Public Accountants Act of Japan.

Accounting Auditor's Audit Report on the Non-consolidated Financial Statements (duplicated copy)

Independent Auditor's Report

(English Translation)

May 10, 2021

To the Board of Directors NIHON NOHYAKU CO., LTD.

Kyowa Audit Corporation Chiyoda-ku, Tokyo Masashige Takayama, CPA Representative Partner Engagement Partner Masashi Ozawa, CPA Representative Partner Engagement Partner

Opinion

Pursuant to Article 436, Paragraph 2, Item 1 of the Companies Act, we have audited the accompanying financial statements, which comprise the non-consolidated balance sheet, the non-consolidated statement of income, the non-consolidated statement of changes in equity and the related notes, and the accompanying supplementary schedules of NIHON NOHYAKU CO., LTD. (the "Company") for the 122nd fiscal year from April 1, 2020 through March 31, 2021.

In our opinion, the financial statements and the accompanying supplementary schedules referred to above present fairly, in all material respects, the financial position of the Company as of March 31, 2021, and the results of its operations for the year then ended in conformity with accounting principles generally accepted in Japan.

Basis for the Opinion

We conducted our audit in accordance with auditing standards generally accepted in Japan. Our responsibility under the auditing standards is stated in "Auditor's Responsibility for the Audit of the Financial Statements and the Accompanying Supplementary Schedules." We are independent of the Company in accordance with the provisions related to professional ethics in Japan, and are fulfilling other ethical responsibilities as an auditor. We believe that we have obtained sufficient and appropriate audit evidence to provide a basis for our audit opinion.

Responsibilities of Management and the Audit & Supervisory Committee for the Financial Statements and the Accompanying Supplementary Schedules

Management is responsible for the preparation and fair presentation of the financial statements and the accompanying supplementary schedules in accordance with accounting principles generally accepted in Japan, and for designing and operating such internal control as management determines is necessary to enable the preparation and fair presentation of the financial statements and the accompanying supplementary schedules that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements and the accompanying supplementary schedules, management is responsible for assessing whether it is appropriate to prepare the financial statements and the accompanying supplementary schedules in accordance with the premise of a going concern, and for disclosing matters relating to going concern when it is required to do so in accordance with accounting principles generally accepted in Japan.

The Audit & Supervisory Committee is responsible for monitoring the execution of Directors' duties related to designing and operating the financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements and the Accompanying Supplementary Schedules

Our responsibility is to obtain reasonable assurance about whether the financial statements and the accompanying supplementary schedules as a whole are free from material misstatement, whether due to fraud or error, and to express an opinion on the financial statements and the accompanying supplementary schedules from an independent standpoint in an audit report, based on our audit. Misstatements can occur as a result of fraud or error, and are deemed material if they can be reasonably expected to, either individually or collectively, influence the decisions of users taken on the basis of the financial statements and the accompanying supplementary schedules.

We make professional judgment in the audit process in accordance with auditing standards generally accepted in Japan, and perform the following while maintaining professional skepticism.

- Identify and assess the risks of material misstatement, whether due to fraud or error. Design and implement audit procedures to address the risks of material misstatement. The audit procedures shall be selected and applied as determined by the auditor. In addition, sufficient and appropriate audit evidence shall be obtained to provide a basis for the audit opinion.
- In making those risk assessments, the auditor considers internal control relevant to the entity's audit in order to design audit procedures that are appropriate in the circumstances, although the purpose of the audit of the financial statements and the accompanying supplementary schedules is not to express an opinion on the effectiveness of the entity's internal control.
- Assess the appropriateness of accounting policies adopted by management and the method of their application, as well as the reasonableness of accounting estimates made by management and the adequacy of related notes.
- Determine whether it is appropriate for management to prepare the financial statements and the accompanying supplementary schedules on the premise of a going concern and, based on the audit evidence obtained, determine whether there is a significant uncertainty in regard to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If there is a significant uncertainty concerning the premise of a going concern, the auditor is required to call attention to the notes to the financial statements and the accompanying supplementary schedules in the audit report, or if the notes to the financial statements and the accompanying supplementary schedules pertaining to the significant uncertainty are inappropriate, issue a modified opinion on the financial statements and the accompanying optimized optimized on the audit evidence obtained up to the date of the audit report, depending on future events or conditions, an entity may be unable to continue as a going concern.
- Besides assessing whether the presentation of and notes to the financial statements and the accompanying supplementary schedules are in accordance with accounting principles generally accepted in Japan, assess the presentation, structure, and content of the financial statements and the accompanying supplementary schedules including related notes, and whether the financial statements and the accompanying supplementary schedules fairly present the transactions and accounting events on which they are based.

The auditor reports to the Audit & Supervisory Committee regarding the scope and timing of implementation of the planned audit, material audit findings including material weaknesses in internal control identified in the course of the audit, and other matters required under the auditing standards.

The auditor reports to the Audit & Supervisory Committee regarding the observance of provisions related to professional ethics in Japan as well as matters that are reasonably considered to have an impact on the auditor's independence and any safeguards that are in place to reduce or eliminate obstacles.

Interest

Our firm and engagement partners have no interests in the Company requiring disclosure under the provisions of the Certified Public Accountants Act of Japan.

Audit & Supervisory Committee's Audit Report (duplicated copy)

Audit Report

(English Translation)

The Audit & Supervisory Committee audited the performance of duties by the Directors for the 122nd fiscal year from April 1, 2020 to March 31, 2021, and hereby submits the method and results of the audit.

1. Summary of Auditing Methods

The Audit & Supervisory Committee received reports periodically from Directors, employees and other relevant personnel about the details of Board of Directors' resolutions concerning the matters set forth in Article 399-13, Paragraph 1, Item 1 (b) and (c) of the Companies Act, as well as the establishment and application of the internal control systems based on such resolutions, and then sought explanations as necessary, expressed opinions and conducted the audit through the methods described below.

- (1) In conformity with the Auditing Standards, etc. of the Audit & Supervisory Committee established by the Audit & Supervisory Committee, following the auditing policies, allocation of duties and other relevant matters, using means such as the Internet, etc. and cooperating with the internal audit division and other internal control divisions, we participated in important meetings, received reports from the Directors, employees and other relevant personnel regarding performance of their duties, sought explanations as necessary, examined important authorized documents and associated information, and studied the operations and financial positions at the head office and principal business offices. With respect to subsidiaries, using means such as the Internet, etc., we communicated with, and collected information from, Directors, Audit & Supervisory Board Members and other relevant personnel of subsidiaries as well as received reports from subsidiaries on their business as necessary.
- (2) We monitored and verified whether the Accounting Auditor maintained its independence and implemented appropriate audits, as well as received reports from the Accounting Auditor regarding the performance of its duties and sought explanations as necessary. In addition, we received notice from the Accounting Auditor that "system to ensure that duties are performed properly" (matters set forth in each item of Article 131 of the Regulation on Corporate Accounting) had been prepared in accordance with the "Quality Control Standard for Audit" (issued by the Business Accounting Council on October 28, 2005) and other relevant standards, and sought explanations as necessary. Also, with respect to key audit matters, we discussed with the Accounting Auditor and received reports regarding the performance of its audit and sought explanations as necessary.

Based on the above methods, we examined the Business Report and the supplementary schedules thereof, the non-consolidated financial statements (non-consolidated balance sheet, non-consolidated statement of income, non-consolidated statement of changes in equity, and non-consolidated notes) and the supplementary schedules thereof, as well as the consolidated financial statements (consolidated balance sheet, consolidated statement of income, consolidated statement of changes in equity and consolidated notes) related to the relevant fiscal year.

- 2. Results of Audit
 - (1) Results of Audit of Business Report and Other Relevant Documents
 - 1. In our opinion, the Business Report and the supplementary schedules are in accordance with the related laws and regulations, and Articles of Incorporation, and fairly represent the Company's condition.
 - 2. We have found no evidence of wrongful action or material violation of related laws and regulations, nor of any violation with respect to the Articles of Incorporation, related to performance of duties by the Directors.
 - 3. In our opinion, the contents of the resolutions of the Board of Directors related to the internal controls system are fair and reasonable. In addition, we have found no matters on which to remark regarding the description in the Business Report and the performance of duties by the Directors related to such internal controls system.
 - (2) Results of Audit of Non-consolidated Financial Statements and Supplementary Schedules

In our opinion, the methods and results employed and rendered by Kyowa Audit Corporation are fair and reasonable.

(3) Results of Audit of Consolidated Financial Statements

In our opinion, the methods and results employed and rendered by Kyowa Audit Corporation are fair and reasonable.

May 11, 2021

Audit & Supervisory Committee, NIHON NOHYAKU CO., LTD.

Full-time Audit & Supervisory	Yoshiaki Higashino
Committee Member	
Audit & Supervisory Committee	Haruhiko Tomiyasu
Member	
Audit & Supervisory Committee	Iwao Toigawa
Member	
Audit & Supervisory Committee	Chizuko Nakata
Member	
Audit & Supervisory Committee	Yoshiko Oshima
Member	

(Note) Audit & Supervisory Committee Members, Mr. Iwao Toigawa, Ms. Chizuko Nakata and Ms. Yoshiko Oshima are Outside Directors as stipulated in Article 2, Item 15 and Article 331, Paragraph 6 of the Companies Act.